

**NEW INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION
AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM**

The present invention relates to new indolizine compounds, to a process for their preparation and to pharmaceutical compositions containing them.

The compounds of the present invention are new and have very valuable pharmacological characteristics in the field of apoptosis and cancerology.

5 Apoptosis, or programmed cell death, is a physiological process that is crucial for embryonic development and maintenance of tissue homeostasis.


Apoptotic-type cell death involves morphological changes such as condensation of the nucleus, DNA fragmentation and also biochemical phenomena such as the activation of caspases which cause damage to key structural components of the cell, so inducing its
10 disassembly and death. Regulation of the process of apoptosis is complex and involves the activation or repression of several intracellular signalling pathways (Cory S. *et al.*, Nature Review Cancer, 2002, 2, 647-656).

Deregulation of apoptosis is involved in certain pathologies. Increased apoptosis is associated with neurodegenerative diseases such as Parkinson's disease, Alzheimer's
15 disease and ischaemia. Conversely, deficits in the implementation of apoptosis play a significant role in the development of cancers and their chemoresistance, in auto-immune diseases, inflammatory diseases and viral infections. Accordingly, absence of apoptosis is one of the phenotypic signatures of cancer (Hanahan D. *et al.*, Cell 2000, 100, 57-70).

The anti-apoptotic proteins of the Bcl-2 family are associated with numerous pathologies.
20 The involvement of proteins of the Bcl-2 family is described in numerous types of cancer, such as colon cancer, breast cancer, small-cell lung cancer, non-small-cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphoid leukaemia, follicular lymphoma, myeloma, prostate cancer, etc. Overexpression of the anti-apoptotic proteins of the Bcl-2 family is involved in tumorigenesis, in resistance to chemotherapy and in the
25 clinical prognosis of patients affected by cancer. There is, therefore, a therapeutic need for compounds that inhibit the anti-apoptotic activity of the proteins of the Bcl-2 family.


In addition to being new, the compounds of the present invention have pro-apoptotic properties making it possible to use them in pathologies involving a defect in apoptosis, such as, for example, in the treatment of cancer and of immune and auto-immune diseases.

The present invention relates more especially to compounds of formula (I):



wherein:

- ♦ X and Y represent a carbon atom or a nitrogen atom, it being understood that they may not simultaneously represent two carbon atoms or two nitrogen atoms,

- ♦ the Het moiety of the group  represents an optionally substituted, aromatic or non-aromatic ring composed of 5, 6 or 7 ring members, which may contain, in addition to the nitrogen represented by X or by Y, from one to 3 hetero atoms selected independently from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom, a linear or branched (C₁-C₆)alkyl group or a group -C(O)-O-Alk wherein Alk is a linear or branched (C₁-C₆)alkyl group,

- ♦ R₁ and R₂ independently of one another represent a hydrogen atom or a linear or branched (C₁-C₆)alkyl group,

or R₁ and R₂ form with the nitrogen atom carrying them a heterocycloalkyl composed of from 4 to 7 ring members, which may contain, in addition to the nitrogen atom, another hetero atom selected from oxygen, sulphur, SO₂ and NR wherein R represents a hydrogen atom, a linear or branched (C₁-C₆)alkyl group, a (C₁-C₆)alkylsulphonyl group, a linear or branched (C₁-C₆)polyhaloalkyl group or a group -C(O)-O-Alk wherein Alk is a linear or branched (C₁-C₆)alkyl group,

♦ R₃ represents a linear or branched (C₁-C₆)alkyl group, a (C₂-C₆)alkenyl group, a (C₂-C₆)alkynyl group, a cycloalkyl group, a (C₄-C₁₀)cycloalkyl-(C₁-C₆)alkyl group wherein the alkyl group may be linear or branched, an aryl group or a heteroaryl group,

♦ R₄ represents an aryl, heteroaryl, cycloalkyl or linear or branched (C₁-C₆)alkyl group,


♦ R₅ represents a hydrogen atom or a halogen atom,

♦ R_a, R_b, R_c and R_d independently of one another represent a hydrogen atom, a halogen atom, a linear or branched (C₁-C₆)alkyl group, a linear or branched (C₁-C₆)alkoxy group, a hydroxy group, a linear or branched (C₁-C₆)polyhaloalkyl group, or a trifluoromethoxy group, or the substituents of one of the pairs (R_a,R_b), (R_b,R_c) or (R_c,R_d) form together with the carbon atoms carrying them a ring composed of from 5 to 7 ring members, which may contain from one to 3 hetero atoms selected from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom, a linear or branched (C₁-C₆)alkyl group or a group -C(O)-O-Alk wherein Alk is a linear or branched (C₁-C₆)alkyl group, it also being understood that one or more carbon atoms of the ring defined hereinbefore may be deuterated,

it being understood that:

- "aryl" means a phenyl, naphthyl, biphenyl or indenyl group,
- "heteroaryl" means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 hetero atoms selected from oxygen, sulphur and nitrogen,
- "cycloalkyl" means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 4 to 10 ring members,

it being possible for the alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined to be substituted by from 1 to 3 groups selected from optionally substituted linear or branched (C₁-C₆)alkyl, (C₃-C₆)spiro, linear or branched (C₁-C₆)alkoxy, (C₁-C₆)alkyl-S-, hydroxy, oxo (or *N*-oxide where appropriate), nitro, cyano, -COOR', NR'R'', linear or
5 branched (C₁-C₆)polyhaloalkyl, trifluoromethoxy, (C₁-C₆)alkylsulphonyl or halogen, it being understood that R' and R'' independently of one another represent a hydrogen atom or a linear or branched (C₁-C₆)alkyl group,


it being possible for the Het moiety of the group  defined hereinbefore to be
10 substituted by a group selected from linear or branched (C₁-C₆)alkyl, hydroxy, NR₁'R₁'' and halogen, it being understood that R₁' and R₁'' have the same definitions than the groups R' and R'' mentioned hereinbefore,

to their enantiomers and diastereoisomers, and to addition salts thereof with a pharmaceutically acceptable acid or base.

15 Among the pharmaceutically acceptable acids there may be mentioned, without implying any limitation, hydrochloric acid, hydrobromic acid, sulphuric acid, phosphonic acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulphonic acid, camphoric acid etc.

20 Among the pharmaceutically acceptable bases there may be mentioned, without implying any limitation, sodium hydroxide, potassium hydroxide, triethylamine, *tert*-butylamine etc.

The group:



25 advantageously represents one of the following groups: 5,6,7,8-tetrahydroindolizine optionally substituted by a hydroxy, indolizine, 1,2,3,4-tetrahydropyrrolo[1,2-*a*]pyrazine, *tert*-butyl 3,4-dihydropyrrolo[1,2-*a*]pyrazine-2(1*H*)-carboxylate, 3,4-dihydro-1*H*-

pyrrolo[2,1-*c*][1,4]oxazine, 2,3-dihydro-1*H*-pyrrolizine optionally substituted by a hydroxy, 6,7,8,9-tetrahydro-5*H*-pyrrolo[1,2-*a*]azepine or pyrrolo[1,2-*a*]pyrazine.

In the preferred compounds of the invention, R₁ and R₂ each represents an alkyl group optionally substituted by a methoxy, or R₁ and R₂ form with the nitrogen atom carrying them a heterocycloalkyl selected from the following groups: morpholine optionally substituted by one or more linear or branched (C₁-C₆)alkyl(s), oxidomorpholine, thiomorpholine 1,1-dioxide, 1,4-oxazepan, 3-methoxypyrrolidine, 3,3-difluoropyrrolidine, 3-methoxyazetidine, 3-fluoroazetidine, oxopiperazine or piperazine, the last two groups being substituted by a linear or branched (C₁-C₆)alkyl group, a linear or branched (C₁-C₆)-polyhaloalkyl group or a methylsulphonyl group.

Preferably, R_a and R_d each represents a hydrogen atom and (R_b,R_c) form together with the carbon atoms carrying them a 1,3-dioxolane group wherein one of the carbon atoms is optionally deuterated, a 1,4-dioxane group, a 1,4-dioxepane group, or R_a, R_c and R_d each represents a hydrogen atom and R_b represents a halogen, a methyl, a methoxy, an ethoxy, a trifluoromethyl or a trifluoromethoxy.

The preferred group R₄ is a 4-hydroxyphenyl, 3-fluoro-4-hydroxyphenyl or 5-hydroxypyrimidine.

In the preferred compounds, R₃ represents a group selected from phenyl, indole, indoline, 1,2,3,4-tetrahydroquinoline, 3,4-dihydro-2*H*-1,4-benzoxazine, indane, 1*H*-indazole, 1*H*-pyrrolo[2,3-*b*]pyridine, pyrimidine, cyclobutylmethyl, cyclopropylmethyl, 1*H*-pyrazole, pyridine, pyridazine, those groups optionally having one or more substituents selected from halogen, linear or branched (C₁-C₆)alkyl, cyano and linear or branched (C₁-C₆)-alkoxy.

The preferred compounds of the invention are listed below:


- *N*-(4-hydroxyphenyl)-3-{6-[(*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl}-*N*-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide,

- 3-{5-chloro-2-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- *N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indazol-5-yl)-3-{2,2-dideuterio-6-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- *N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indazol-5-yl)-3-(6-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide,
- *N*-(4-hydroxyphenyl)-3-{7-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-2,3-dihydro-1,4-benzodioxin-6-yl}-*N*-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- *N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-{6-[[[(3*S*)-3-[(4-methyl-1-piperazinyl)methyl]-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl]-1-indolizine carboxamide,
- *N*-[4-(hydroxy)phenyl]-*N*-(1-methyl-1*H*-indol-5-yl)-3-{6-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- *N*-(4-hydroxyphenyl)-3-{6-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-*N*-phenyl-1-indolizine carboxamide,
- 3-{5-chloro-2-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-1-indolizine carboxamide,
- 6-{5-chloro-2-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(3-fluoro-4-methylphenyl)-*N*-(4-hydroxyphenyl)-3,4-dihydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine-8-carboxamide,
- 3-(5-chloro-2-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}phenyl)-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-pyrazol-4-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide,
- *N*-(3-fluoro-4-methylphenyl)-*N*-(4-hydroxyphenyl)-3-{6-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide,

- *N*-[4-(hydroxy)phenyl]-*N*-(1-methyl-2,3-dihydro-1*H*-indol-5-yl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- 3-{5-chloro-2-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-2,3-dihydro-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- *N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-1-indolizine carboxamide,
- 3-{5-chloro-2-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-2,3-dihydro-1*H*-indol-5-yl)-1-indolizine carboxamide,
- 6-{5-chloro-2-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-phenyl-3,4-dihydro-1*H*-pyrrolo[2,1-*c*]-[1,4]oxazine-8-carboxamide,
- *N*-(3-fluorophenyl)-*N*-(4-hydroxyphenyl)-3-(6-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide,


their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.

The invention relates also to a process for the preparation of compounds of formula (I), which process is characterised in that there is used as starting material the compound of formula (II):




wherein R_a , R_b , R_c and R_d are as defined for formula (I),

which compound of formula (II) is subjected to a Heck reaction, in an aqueous or organic medium, in the presence of a palladium catalyst, of a base, of a phosphine and of the compound of formula (III):




wherein the groups X, Y and Het are as defined for formula (I),

5 to obtain the compound of formula (IV):




wherein R_a , R_b , R_c , R_d , X, Y and Het are as defined for formula (I),

the aldehyde function of which compound of formula (IV) is oxidised to the carboxylic acid to form the compound of formula (V):




wherein R_a , R_b , R_c , R_d , X, Y and Het are as defined for formula (I),

which compound of formula (V) is then subjected to peptide coupling with a compound of formula (VI):



wherein R_1 , R_2 and R_5 are as defined for formula (I),

5 to yield the compound of formula (VII):



wherein R_a , R_b , R_c , R_d , R_1 , R_2 , R_5 , X, Y and Het are as defined for formula (I),

the ester function of which compound of formula (VII) is hydrolysed to yield the carboxylic acid or the corresponding carboxylate, which may be converted into an acid derivative such as acyl chloride or the corresponding anhydride before being coupled with an amine NHR_3R_4 wherein R_3 and R_4 have the same meanings as for formula (I), to yield
5 the compound of formula (I),

which compound of formula (I) may be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and which is optionally separated into its isomers according to a conventional separation technique,

10 it being understood that at any moment considered appropriate during the course of the process described above, some groups (hydroxy, amino...) of the starting reagents or of the synthesis intermediates can be protected and subsequently deprotected, as required by the synthesis,

More particularly, when one of the groups R_3 or R_4 of the amine NHR_3R_4 is substituted by a hydroxy function, the latter may be subjected beforehand to a protection reaction prior to coupling with the carboxylic acid formed from the compound of formula (VII), or with a corresponding acid derivative thereof, the resulting protected compound of formula (I) subsequently undergoes a deprotection reaction and is then optionally converted into one of its addition salts with a pharmaceutically acceptable acid or base.
15

20 The compounds of formulae (II), (III), (VI) and the amine NHR_3R_4 are either commercially available or can be obtained by the person skilled in the art using conventional chemical reactions described in the literature.

Pharmacological study of the compounds of the invention has shown that they have pro-apoptotic properties. The ability to reactivate the apoptotic process in cancerous cells is of major therapeutic interest in the treatment of cancers and of immune and auto-immune diseases.
25

More especially, the compounds according to the invention will be useful in the treatment of chemo- or radio-resistant cancers, and in malignant haemopathies and small-cell lung cancer.

Among the cancer treatments envisaged there may be mentioned, without implying any limitation, cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, follicular lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer and small-cell lung cancer.

The present invention relates also to pharmaceutical compositions comprising at least one compound of formula (I) in combination with one or more pharmaceutically acceptable excipients.

Among the pharmaceutical compositions according to the invention there may be mentioned more especially those that are suitable for oral, parenteral, nasal, per- or trans-cutaneous, rectal, perlingual, ocular or respiratory administration, especially tablets or dragées, sublingual tablets, sachets, paquets, capsules, glossettes, lozenges, suppositories, creams, ointments, dermal gels, and drinkable or injectable ampoules.

The dosage varies according to the sex, age and weight of the patient, the administration route, the nature of the therapeutic indication, or of any associated treatments, and ranges from 0.01 mg to 1 g per 24 hours in one or more administrations.

Furthermore, the present invention relates also to the association of a compound of formula (I) with an anticancer agent selected from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors, kinase inhibitors and antibodies, and also to pharmaceutical compositions comprising that type of association and their use in the manufacture of medicaments for use in the treatment of cancer.

The compounds of the invention may also be used in association with radiotherapy in the treatment of cancer.

The following Preparations and Examples illustrate the invention but do not limit it in any way.

Preparation 1: 6-[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-3-indolizinyl]-1,3-benzodioxole-5-carboxylic acid

5 **Step A: 1-Formyl-2-piperidinecarboxylic acid**

To a solution of 40 g of a racemic mixture of 2-piperidinecarboxylic acid (0.310 mmol) in 300 mL of formic acid at 0°C there are added dropwise 200 mL (2.15 mmol) of acetic anhydride. The whole is then stirred at ambient temperature overnight. The reaction mixture is then cooled to 0°C, hydrolysed by the addition of 250 mL of water and stirred
10 for half an hour at 0°C before being concentrated to dryness. The oil so obtained is taken up in 200 mL of methanol and then concentrated to dryness. The title product is obtained in the form of an oil with a yield of 98%. It is used directly, without further purification, for the following step.

¹H-NMR: δ (400 MHz; dmso-d₆; 300°K): 13.0 (m, 1H OH); 8.0-8.05 (2s, 1H aldehyde);
15 4.9-4.5 (2d, 1H α of N and COOH); 4.1-2.6 (m, 2H to α of N); 2.2-1.2 (m, 6H piperidine).
IR: ν: -OH: 2000-3000 cm⁻¹ acid; ν: >C=O 1703 cm⁻¹ broad band.

Step B: Methyl 5,6,7,8-tetrahydro-1-indolizinecarboxylate

To a solution of 10 g of carboxylic acid obtained in Step A (63.6 mmol) in 65 mL of dichloroethane there are added in succession 13.4 g of tosyl chloride (70.4 mmol), 11.5 mL
20 of methyl 2-chloroacrylate (113.5 mmol) and then, dropwise, 17.8 mL of *N,N,N*-triethylamine (127.2 mmol). The reaction mixture is then refluxed for 1.5 hours. It is then brought to ambient temperature, and then 5 mL of methyl 2-chloroacrylate (48.9 mmol) and, dropwise, 9 mL of *N,N,N*-triethylamine (64 mmol) are added. The whole is heated at reflux overnight.

25 The reaction mixture is subsequently diluted with methylene chloride, washed in succession with a 1N HCl solution, a saturated NaHCO₃ solution and then a saturated NaCl solution until a neutral pH is obtained. The organic phase is then dried over MgSO₄,

filtered, concentrated to dryness, and purified by chromatography over silica gel (heptane/AcOEt gradient). The title product is obtained in the form of an oil.

¹H-NMR: δ (400 MHz; CDCl₃; 300°K): 6.55-6.40 (d, 2H, tetrahydroindolizine); 3.91 (t, 3H methyl ester); 3.78 (s, 3H tetrahydroindolizine); 3.08 (t, 2H, tetrahydroindolizine);
5 1.95-1.85 (m, 4H, tetrahydroindolizine)

IR: ν :>C=O 1692 cm⁻¹ ester

Step C: Methyl 3-(6-formyl-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydro-1-indolizine-carboxylate

To a solution of 6.4 g of the ester obtained in Step B (35.7 mmol) in 12 mL of *N,N*-dimethylacetamide there are added in succession 12.3 g of 6-bromo-1,3-benzodioxole-5-carbaldehyde (53.6 mmol) and 7 g of potassium acetate (71.4 mmol), and the whole is then stirred under argon for 20 minutes. 1.3 g of palladium catalyst PdCl₂(PPh₃)₂ (1.8 mmol) are then added. The reaction mixture is subsequently heated at 130°C for one hour before 139 μ L of H₂O are added thereto. Heating is maintained at that same temperature
10 overnight. The mixture is allowed to return to ambient temperature and is then diluted with AcOEt. Animal charcoal is added (2 g per g of product) and the whole is stirred at ambient temperature for one hour and then filtered. The organic phase is then washed with water, dried over magnesium sulphate and concentrated to dryness. The crude product so obtained is purified on silica gel (heptane/AcOEt gradient). The title product is obtained in the form
15 of an oil.
20

¹H-NMR: δ : (400 MHz; dms_o-d₆; 353°K): 9.65 (s, 1H, H aldehyde); 7.3-7.15 (2s, 2H, H aromatic); 6.45 (s, 1H tetrahydroindolizine); 6.20 (s, 2H methylenedioxy); 3.70 (s, 3H methyl ester); 3.5-4.0 (m, 2H tetrahydroindolizine); 3.05 (m, 2H tetrahydroindolizine); 1.85 (m, 4H tetrahydroindolizine)

IR: ν : >C=O 1695 cm⁻¹ ester; ν : >C=O 1674 cm⁻¹

Step D: 6-[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-3-indoliziny]-1,3-benzodioxole-5-carboxylic acid

There is prepared a solution containing 3.37 g of the compound obtained in Step C (10.3 mmol) in 9.3 mL of acetone and 8.8 mL (80.24 mmol) of 2-methyl-2-butene, which solution is placed at 0°C. There are added, dropwise, 9.3 mL of an aqueous solution containing a mixture of 3.3 g of NaClO₂ (36.05 mmol) and 3.6 g of Na₂PO₄ (25.75 mmol). The whole is subsequently stirred at ambient temperature for 7 hours. The reaction mixture is then concentrated in order to remove the acetone. The solid then obtained is filtered, washed with water and then dried *in vacuo* at 40°C overnight. The title product is obtained in the form of a solid, which is used subsequently without being purified further.

¹H-NMR: δ (400 MHz; dmso-d₆; 300°K): 12.10 (m, 1H, H carboxylic acid); 7.40-6.88 (2s, 2H, H aromatic); 6.20 (s, 1H, H tetrahydroindolizine); 6.18 (s, 2H, H methylenedioxy); 3.70 (s, 3H, methyl ester); 3.55 (t, 2H tetrahydroindolizine); 3.00 (t, 2H tetrahydroindolizine); 1.80 (m, 4H, H tetrahydroindolizine)

IR: v: -OH: 3000-2000 cm⁻¹ acid; v: >C=O 1686-1676 cm⁻¹ ester+acid; v: >C=C< 1608 cm⁻¹

Preparation 2: 4-Bromo-2-[1-(methoxycarbonyl)-5,6,7,8-tetrahydro-3-indoliziny]-benzoic acid

The procedure is as in the process of Preparation 1, replacing the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C by 2,4-dibromobenzaldehyde. There is obtained a mixture of two regioisomers, which are separated by chromatography.

Preparation 3: 4-Chloro-2-[1-(methoxycarbonyl)-5,6,7,8-tetrahydro-3-indoliziny]-benzoic acid

The procedure is as in the process of Preparation 1, replacing the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C by 2-bromo-4-chlorobenzaldehyde.

Preparation 4: 4-Fluoro-2-[1-(methoxycarbonyl)-5,6,7,8-tetrahydro-3-indoliziny]-benzoic acid

The procedure is as in the process of Preparation 1, replacing the 6-bromo-1,3-

benzodioxole-5-carbaldehyde used in Step C by 2-bromo-4-fluorobenzaldehyde.

Preparation 5: 8-[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-3-indoliziny]-3,4-dihydro-2H-1,5-benzodioxepine-7-carboxylic acid

The procedure is as in the process of Preparation 1, replacing the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C by 8-bromo-3,4-dihydro-2H-1,5-benzodioxepine-7-carbaldehyde.

Preparation 6: 4-Methoxy-2-[1-(methoxycarbonyl)-5,6,7,8-tetrahydro-3-indoliziny]-benzoic acid

The procedure is as in the process of Preparation 1, replacing the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C by 2-bromo-4-methoxybenzaldehyde.

Preparation 7: 7-[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-3-indoliziny]-2,3-dihydro-1,4-benzodioxine-6-carboxylic acid

The procedure is as in the process of Preparation 1, replacing the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C by 7-bromo-2,3-dihydro-1,4-benzodioxine-6-carbaldehyde.

Preparation 8: 4-Ethoxy-2-[1-(methoxycarbonyl)-5,6,7,8-tetrahydro-3-indoliziny]-benzoic acid

The procedure is as in the process of Preparation 1, replacing the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C by 2-bromo-4-ethoxybenzaldehyde.

Preparation 9: 2,2-Dideuterio-6-[1-(methoxycarbonyl)-5,6,7,8-tetrahydro-3-indoliziny]-1,3-benzodioxole-5-carboxylic acid

Step A: 2,2-Dideuterio-1,3-benzodioxole-5-carbaldehyde

To a solution of 30 g of 3,4-dihydroxybenzaldehyde (217 mmol) in 110 mL of anhydrous DMF there are added in succession 114 g of caesium carbonate (347 mmol) and 22 mL of dideuterated methylene chloride (347 mmol). The reaction mixture is subsequently stirred at ambient temperature overnight. After filtering off the insoluble portion over Celite, the

residual filtrate is subsequently hydrolysed by addition of 200 mL of water and then extracted with ethyl acetate. The organic phases are then combined, washed with a saturated LiCl solution and then dried over MgSO₄. After concentration to dryness, the residue is purified by chromatography over silica gel (petroleum ether/AcOEt gradient).

5 The title product is obtained in the form of a solid.

¹H-NMR: δ: (400 MHz; dms_o-d₆; 300°K): 9.8 (s, 1H, H aldehyde); 7.4-6.95 (m, 3H, H aromatic)

IR: ν: C=O aldehyde: 1670 cm⁻¹

Step B: 6-Bromo-2,2-dideuterio-1,3-benzodioxole-5-carbaldehyde

10 To a solution of 10 g of the compound obtained in Step A (65.7 mmol) in 100 mL of methanol cooled to 0°C there are added dropwise 3.7 mL of a solution of bromine (1.1 molar equivalents) in 10 mL of methanol. The whole is subsequently stirred at ambient temperature overnight. The reaction mixture is concentrated to dryness and then taken up in water. After stirring, the resulting solid is subsequently filtered and then dried.

15 **¹H-NMR:** δ (400 MHz; dms_o-d₆; 300°K): 10.2 (s, 1H, H aldehyde); 7.4 (s, 1H, H aromatic); 7.05 (s, 1H, H aromatic)

IR: ν: C=O aldehyde: 1670 cm⁻¹; C=C aromatic: 1611 cm⁻¹

Step C: 2,2-Dideuterio-6-[1-(methoxycarbonyl)-5,6,7,8-tetrahydro-3-indoliziny]-1,3-benzodioxole-5-carboxylic acid

20 The procedure is as in the protocol described in Steps C and D of Preparation 1, replacing the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C by 6-bromo-2,2-dideuterio-1,3-benzodioxole-5-carbaldehyde.

Preparation 10: 2-[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-3-indoliziny]-4-(trifluoromethyl)benzoic acid

25 The procedure is as in the protocol described in Preparation 1, replacing the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C by 2-bromo-4-(trifluoromethyl)benzaldehyde.

Preparation 11: 2-[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-3-indoliziny]-4-(trifluoromethoxy)benzoic acid

The procedure is as in the protocol described in Preparation 1, replacing the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C by 2-bromo-4-(trifluoromethoxy)-benzaldehyde.

Preparation 12: 2-[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-3-indoliziny]benzoic acid

The procedure is as in the protocol described in Preparation 1, replacing the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C by 2-bromobenzaldehyde.

Preparation 13: 6-[1-(Methoxycarbonyl)-3-indoliziny]-1,3-benzodioxole-5-carboxylic acid

Step A: 1-(Carboxymethyl)-1,2-dihydropyridinium bromide

To a solution of 16.2 mL of pyridine (200 mmol) in 120 mL of ethyl acetate there are added in portions 27.8 g (200 mmol) of bromoacetic acid. The whole is subsequently stirred at ambient temperature overnight. The precipitate so obtained is filtered off and then washed with cold ethyl acetate. After drying, the title product is obtained in the form of a powder, which is used directly for the following step.

¹H-NMR: δ (400 MHz; dmso-d₆; 300°K): 9.15 (d, 2H, H aromatic pyridine); 8.7 (t, 1H, H aromatic); 8.25 (t, 2H, H aromatic); 5.65 (s, 2H, H CH₂COOH)

IR: ν : C=O: 1732 cm⁻¹; -OH acid: 2800 cm⁻¹

Step B: Methyl 1-indolizinecarboxylate

To a suspension of 6.55 g of the pyridinium salt obtained in Step A (30 mmol) in 240 mL of toluene there are added in succession 16.7 mL of methyl acrylate (150 mmol), 4.2 mL of triethylamine (30 mmol) and then, in portions, 20.9 g of MnO₂ (240 mmol). The whole is subsequently heated at 90°C for 3 hours. After cooling, the reaction mixture is filtered over a Celite cake and concentrated to dryness. The title product is then isolated by purification on silica gel (heptane/AcOEt gradient: 0-10%) in the form of an oil, which crystallises when cold.

¹H-NMR: δ (300 MHz; dmso-d₆; 300°K): 8.5 (d, 1H, H indolizine); 8.05 (d, 1H, H indolizine); 7.6 (s, 1H, H indolizine); 7.15 (m, 2H, H indolizine); 6.85 (m, 1H, H indolizine); 4.25 (q, 2H, -C(O)CH₂CH₃); 1.35 (t, 3H, -C(O)CH₂CH₃)

IR: v: C=O ester: 1675 cm⁻¹; C=C aromatic: 1634 cm⁻¹

5 **Step C: 6-[1-(Methoxycarbonyl)-3-indoliziny]-1,3-benzodioxole-5-carboxylic acid**

The procedure is as in the protocol described in Steps C and D of Preparation 1.

Preparation 14: 4-Chloro-2-[1-(methoxycarbonyl)-3-indoliziny]benzoic acid

10 Methyl 1-indolizinecarboxylate is formed according to the process described in Steps A and B of Preparation 13. The title product is subsequently obtained according to the protocol described in Steps C and D of Preparation 1, replacing the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C by 2-bromo-4-chlorobenzaldehyde.

Preparation 15: 7-[1-(Methoxycarbonyl)-3-indoliziny]-2,3-dihydro-1,4-benzodioxine-6-carboxylic acid

15 Methyl 1-indolizinecarboxylate is formed according to the process described in Steps A and B of Preparation 13. The title product is subsequently obtained according to the described in Steps C and D of Preparation 1, replacing the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C by 7-bromo-2,3-dihydro-1,4-benzodioxine-6-carbaldehyde.

Preparation 16: 4-Methoxy-2-[1-(methoxycarbonyl)-3-indoliziny]benzoic acid

20 Methyl 1-indolizinecarboxylate is formed according to the process described in Steps A and B of Preparation 13. The title product is subsequently obtained according to the protocol described in Steps C and D of Preparation 1, replacing the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C by 2-bromo-4-methoxybenzaldehyde.

Preparation 17: 6-[2-(tert-Butoxycarbonyl)-8-(methoxycarbonyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-6-yl]-1,3-benzodioxole-5-carboxylic acid

Step A: 1-tert-Butyl 3-methyl 4-formyl-1,3-piperazinedicarboxylate

To a solution of pentafluorophenol in 520 mL of anhydrous ether at 0°C there are added in succession 49 g of 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide (286 mmol) in portions and 12 mL of formic acid (312 mmol). The whole is stirred at ambient temperature for 2 hours. There is subsequently added a mixture of 32 g of 1-tert-butyl 3-methyl 1,3-piperazinedicarboxylate (130 mmol) and 18 mL of triethylamine (130 mmol) in solution in 520 mL of CH₂Cl₂. The whole is stirred overnight at ambient temperature. The reaction mixture is hydrolysed with an 1N aqueous HCl solution and extracted with CH₂Cl₂. The organic phases are subsequently combined and then washed with a saturated aqueous NaHCO₃ solution and then with a saturated aqueous NaCl solution until neutral. After drying over MgSO₄, filtration and concentration to dryness, the product is isolated by chromatography over silica gel (petroleum ether/AcOEt gradient: 0-30%). The title product is obtained in the form of an oil.

IR: ν : C=O: 1674-1745 cm⁻¹

m/z (C₁₂H₂₀N₂O₅): 272.1(M⁺); 295.121 (M+Na)⁺; 567.253 (2M+Na)⁺

Step B: Lithium 4-(tert-butoxycarbonyl)-1-formyl-2-piperazinecarboxylate

To a solution of 28 g of the compound obtained in Step A (103 mmol) in 515 mL of dioxane there are added 4.8 g of LiOH (113 mmol) in solution in 100 mL of H₂O. The whole is stirred at ambient temperature for 4 hours. The reaction mixture is subsequently concentrated to dryness and then co-evaporated several times with ethyl acetate. The title product is obtained in the form of a solid and is used directly for the following cyclisation step.

¹³C-NMR: δ (500 MHz; dmsO-d₆; 300°K): 46 (s, C piperazine); 42-38 (m, C piperazine); 58-53 (s, C piperazine); 28.5 (s, C ^tBu).

IR: ν : C=O: 1650 cm⁻¹; 2800 cm⁻¹

Step C: 2-tert-Butyl 8-methyl 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1H)-dicarboxylate

To a suspension of 29 g of the compound obtained in Step B (103 mmoles) in 800 mL of dichloroethane there are added in succession 24 g of tosyl chloride (124 mmol), 12.6 mL

of methyl 2-chloroacrylate (124 mmol) and then 35 mL of triethylamine (247 mmoles). The whole is stirred at reflux for 2 hours. After cooling, the reaction mixture is diluted with ethyl acetate, and the organic phase is washed with a saturated NaCl solution until neutral. After drying over MgSO₄, filtration and concentration to dryness, the title product is isolated by chromatography over silica gel (petroleum ether/AcOEt gradient: 0-20%) in the form of a solid.

¹H-NMR: δ (400 MHz; dms^o-d₆; 300°K): 6.8-6.43 (m, 2H, H pyrrole); 4.75-3.75 (m, 6H, H piperazine)); 3.73 (s, 3H, H COOCH₃); 1.48 (s, 9H, H ^tBu).

IR: ν : C=O (conjugated ester): 1712 cm⁻¹; C=O (carbamate): 1677cm⁻¹

Step D: **6-[2-(tert-Butoxycarbonyl)-8-(methoxycarbonyl)-1,2,3,4-tetrahydropyrrolo-[1,2-a]pyrazin-6-yl]-1,3-benzodioxole-5-carboxylic acid**

The procedure is as in the protocol described in Steps C and D of Preparation 1.

Preparation 18: **6-[7-(Methoxycarbonyl)-2,3-dihydro-1H-pyrrolizin-5-yl]-1,3-benzodioxole-5-carboxylic acid**

The procedure is as in the protocol described in Preparation 1, replacing the 2-piperidine-carboxylic acid used in Step A by proline.

Preparation 19: **4-Chloro-2-[7-(methoxycarbonyl)-2,3-dihydro-1H-pyrrolizin-5-yl]-benzoic acid**

The procedure is as in the protocol described in Preparation 1, replacing the 2-piperidine-carboxylic acid used in Step A by proline, while the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C is replaced by 2-bromo-4-chlorobenzaldehyde.

Preparation 20: **4-Chloro-2-[8-(methoxycarbonyl)-3,4-dihydro-1H-pyrrolo[2,1-c]-[1,4]oxazin-6-yl]benzoic acid**

The procedure is as in the protocol described in Preparation 1, replacing 2-piperidine-carboxylic acid by 3-morpholinecarboxylic acid, while the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C is replaced by 2-bromo-4-chlorobenzaldehyde.

Preparation 21: 6-[8-(Methoxycarbonyl)-3,4-dihydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-6-yl]-1,3-benzodioxole-5-carboxylic acid

The procedure is as in the protocol described in Preparation 1, replacing 2-piperidine-carboxylic acid by 3-morpholinecarboxylic acid.

5 **Preparation 22: 4-Chloro-2-[1-(methoxycarbonyl)-6,7,8,9-tetrahydro-5*H*-pyrrolo-[1,2-*a*]azepin-3-yl]benzoic acid**

The procedure is as in the protocol described in Preparation 1, replacing 2-piperidine-carboxylic acid by 2-azepanecarboxylic acid, while the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C is replaced by 2-bromo-4-chlorobenzaldehyde.

10 **Preparation 23: 6-[1-(Methoxycarbonyl)-6,7,8,9-tetrahydro-5*H*-pyrrolo[1,2-*a*]azepin-3-yl]-1,3-benzodioxole-5-carboxylic acid**

The procedure is as in the protocol described in Preparation 1, replacing 2-piperidine-carboxylic acid by 2-azepanecarboxylic acid.

15 **Preparation 24: 4-Chloro-2-[3-(methoxycarbonyl)-5,6,7,8-tetrahydro-1-indolizinyl]-benzoic acid**

Step A: Methyl 1-(4-bromobutyl)-1*H*-pyrrole-2-carboxylate

To a suspension of 6.7 g (241.7 mmol) of NaH (60%) in 400 mL of anhydrous THF at 0°C there are added 20 g (161.13 mmol) of methyl 1*H*-pyrrole-2-carboxylate (see *Tetrahedron* **2008**, 64, 7745). The whole is subsequently stirred at ambient temperature for one hour.

20 Then, there are added 95 mL of 1,4-dibromobutane. After the addition, the reaction mixture is heated at reflux for 12 hours. The precipitate obtained is filtered off and then washed with THF. The filtrate is subsequently concentrated to dryness. The compound is then isolated by chromatography over silica gel (cyclohexane/ethyl acetate gradient: 0 to 20%) in the form of an oil.

Elemental microanalysis:

	%C	%H	%N	%Br
<i>Calculated</i>	46.17	5.42	5.38	30.72
<i>Found</i>	46.76	5.56	5.29	30.77

IR: ν : -C=O: 1700 cm^{-1} ; ν : C-O-C: 1238 cm^{-1}

Step B: Methyl 5,6,7,8-tetrahydro-3-indolizinecarboxylate

A solution of 8 g (30.8 mmol) of the brominated derivative obtained in Step A in 700 mL of acetonitrile is brought to reflux. There is added thereto a solution of a mixture of 25 g of azobisisobutyronitrile (151 mmol) and of 30 g of Bu_3SnH (100 mmol) in 500 mL of toluene. The whole is refluxed for 120 hours. The reaction mixture is subsequently concentrated to dryness. The compound is then isolated by chromatography over silica gel (cyclohexane/ethyl acetate gradient 5 to 10%) in the form of an oil.

$^1\text{H-NMR}$: δ (400 MHz; CDCl_3 ; 300°K): 6.90 (d, 1H, H pyrrole); 5.85 (d, 1H, H pyrrole); 4.30 (t, 2H, CH_2 indolizine); 3.80 (s 3H, Me); 2.80 (t, 2H, CH_2 indolizine); 1.95 (m, 2H, CH_2 indolizine); 1.80 (m, 2H, CH_2 indolizine)

IR: ν : -C=O: 1695 cm^{-1}

Step C: 4-Chloro-2-[3-(methoxycarbonyl)-5,6,7,8-tetrahydro-1-indoliziny]benzoic acid

The procedure is as in the protocol described in Steps C and D of Preparation 1.

Preparation 25: 2-[1-(Methoxycarbonyl)-5,6,7,8-tetrahydroindolizin-3-yl]-4-methylbenzoic acid

The procedure is as in the process of Preparation 1, replacing the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C by 2-bromo-4-methylbenzaldehyde.

Preparation 26: 4-Fluoro-2-[8-(methoxycarbonyl)-3,4-dihydro-1H-pyrrolo[2,1-c][1,4]-oxazin-6-yl]benzoic acid

The procedure is as in the protocol described in Preparation 1, replacing 2-piperidine-carboxylic acid by 3-morpholinecarboxylic acid, while the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C is replaced by 2-bromo-4-fluorobenzaldehyde.

Preparation 27: 4-Fluoro-2-[1'-(methoxycarbonyl)-5',6'-dihydro-8'H-spiro[1,3-dioxolane-2,7'-indolizin]-3'-yl]benzoic acid

Step A: Methyl 8-formyl-1,4-dioxo-8-azaspiro[4.5]decane-7-carboxylate

24 g of methyl 1,4-dioxo-8-azaspiro[4.5]decane-9-carboxylate (111 mmol) are dissolved in 80 mL of ethyl acetate and 80 mL of dichloromethane. There are added 26 g of (4-nitrophenyl) formate (155 mmol), and the whole is stirred at ambient temperature for one hour. The reaction mixture is evaporated to dryness and taken up in ethyl acetate. The organic phase is subsequently washed in succession with a 1 N NaOH solution, water, and then with a saturated NH₄Cl solution until a neutral pH is reached. It is subsequently dried over magnesium sulphate, filtered and concentrated to dryness. The oil so obtained is purified by flash chromatography (heptane/ethyl acetate gradient). The title product is obtained in the form of an oil.

¹H-NMR: δ (400 MHz; dmso-d₆; 300°K): 8.15 (s, 1H, CHO); 5.0-4.75 (m, 1H, H tertiary); 4.3-3.7 (m, 5H, 4H ethylenedioxy + 1H aliphatic piperidine); 3.70 (s, 3H, Me); 3.4-2.9 (2m, 1H, H aliphatic piperidine); 2.3-1.75 (m, 2H, H aliphatic piperidine); 1.7-1.5 (m, 2H, H aliphatic piperidine)

Step B: 8-Formyl-1,4-dioxo-8-azaspiro[4.5]decane-7-carboxylic acid

15.25 g of the compound obtained in Step A (62.7 mmol) are dissolved in 160 ml of dioxane. A solution of 125 mL of 1M KOH is added dropwise, and the whole is stirred at ambient temperature for one hour. There are subsequently added 125 mL of 1M HCl, and the compound is extracted with dichloromethane. The organic phase is dried over MgSO₄, filtered and concentrated to dryness. The title product is obtained in the form of a powder.

¹H-NMR: δ (400 MHz; dmso-d₆; 300°K) 13.5-12 (m, 1H, OH); 8.1 + 8.0 (2s, 1H, CHO); 4.9 + 4.6 (2m, 1H, H tertiary); 4.0-3.8 (m, 4H, ethylenedioxy); 4.2 + 3.7 (2ms, 1H, H aliphatic piperidine); 3.4 + 2.9 (2m, 1H, H aliphatic piperidine); 2.4-1.5 (m, 4H, H aliphatic piperidine)

IR: ν : OH: 3500-2000 cm⁻¹; -C=O (acid + aldehyde): 1731 + 1655 cm⁻¹

Step C: Methyl 5',6'-dihydro-8'H-spiro[1,3-dioxolane-2,7'-indolizine]-1'-carboxylate

To a solution of 13.5 g (62.7 mmol) of the acid obtained in Step B in 380 mL of dichloroethane there are added in succession 39.5 mL (238.4 mmol) of triethylamine and then, by spatula, 12.5 g (65.6 mmol) of *para*-toluenesulphonyl chloride and 23.7 mL (238.4 mmol) of methyl chloroacrylate. The whole is stirred at 80°C for 18 hours. The reaction mixture is subsequently filtered over Celite. The filtrate is subsequently washed with a saturated NaHCO₃ solution and then with a saturated NH₄Cl solution. The organic phase is dried over MgSO₄, filtered and concentrated to dryness. The oil so obtained is purified by flash chromatography (heptane/ethyl acetate gradient). The product is obtained in the form of a solid.

¹H-NMR: δ (400 MHz; dms_o-d₆; 300°K) 6.70 (d, 1H, pyrrole); 6.40 (d, 1H, pyrrole); 4.05 (t, 2H, H aliphatic, piperidine); 4.00 (m, 4H, ethylenedioxy); 3.70 (s, 3H, methyl); 3.15 (s, 2H, H aliphatic piperidine); 2.05 (t, 2H, H aliphatic piperidine)

IR: ν:-C=O (ester):1689 cm⁻¹

Step D: Methyl 3'-(5-fluoro-2-formylphenyl)-5',6'-dihydro-8'H-spiro[1,3-dioxolane-2,7'-indolizine]-1'-carboxylate

The procedure is as in the process of Step C of Preparation 1, replacing 6-bromo-1,3-benzodioxole-5-carbaldehyde by 2-bromo-4-fluorobenzaldehyde.

Step E: 4-Fluoro-2-[1'-(methoxycarbonyl)-5',6'-dihydro-8'H-spiro[1,3-dioxolane-2,7'-indolizin]-3'-yl]benzoic acid

The procedure is as in the process of Step D of Preparation 1.

Preparation 28: 4-Fluoro-2-[(2R)-2-hydroxy-7-(methoxycarbonyl)-2,3-dihydro-1H-pyrrolizin-5-yl]benzoic acid

Step A: Methyl (4R)-4-[[tert-butyl(dimethyl)silyl]oxy]-L-prolinate

The protection of the alcohol function of methyl (4R)-4-hydroxy-L-prolinate by a *tert*-butyldimethylsilyl group is carried out according to the protocol described in document

WO 2012040242.

Step B: Methyl (4R)-4-[[tert-butyl(dimethyl)silyl]oxy]-1-formyl-L-prolinate

13.7 g (52.8 mmol) of compound of Step A are dissolved in 100 mL of acetonitrile. There are added thereto 13.2 g (79.3 mmol) of (4-nitrophenyl) formate and 39 mL (238 mmol) of diisopropylethylamine. The whole is stirred at ambient temperature for 6 hours. The reaction mixture is evaporated to dryness and taken up in ethyl acetate. The organic phase is subsequently washed in succession with a 1 N NaOH solution, with water, and then with a saturated NH₄Cl solution until neutral. It is subsequently dried over magnesium sulphate, filtered and concentrated to dryness. The oil so obtained is purified by flash chromatography (gradient: dichloromethane/ammoniacal methanol). The title product is obtained in the form of an oil.

¹H-NMR: δ (400 MHz; dmso-d₆; 300°K): 8.15 and 8.12 (s, 1H, formyl); 4.62 and 4.25 (t, 1H, H alpha ester); 4.40 (m, 1H, SiOCH₃); 3.65 and 3.6 (s, 3H, OMe); 3.5 and 3.3 (m, 2H, 2H proline); 2.12 and 1.95 (m, 2H, 2H proline); 0.8 (s, 9H, Si^tBu); 0.05 (s, 6H, SiMe₂).

IR: v: C=O ester: 1749 cm⁻¹; C=O formyl: 1659 cm⁻¹

Step C: Lithium (2S,4R)-4-[[tert-butyl(dimethyl)silyl]oxy]-1-formylpyrrolidine-2-carboxylate

The compound of Step B (26.2 g; 91.1 mmol) is dissolved in 450 mL of dioxane. A solution of lithium hydroxide (4.2 g; 100 mmol) in water (90 mL) is added. The whole is stirred at ambient temperature for 7 hours. The reaction mixture is evaporated to dryness and used as such for the following step.

Step D: Methyl (2R)-2-[[tert-butyl(dimethyl)silyl]oxy]-2,3-dihydro-1H-pyrrolizine-7-carboxylate

To a solution of 22.4 g (80.2 mmol) of the lithium carboxylate obtained in Step D in 640 mL of dichloroethane there are added in succession 27 mL (192 mmol) of triethylamine and then, in portions, 18 g (96 mmol) of *para*-toluenesulphonic chloride and 9.7 mL (96.2 mmol) of methyl chloroacrylate. The reaction mixture is heated at reflux for 18 hours and then cooled and diluted in ethyl acetate. The organic phase is washed with

water and then with brine, before being dried over MgSO₄. After filtration and concentration of the mixture, the oil obtained is purified by flash chromatography (gradient: heptane/ethyl acetate). The title product is obtained in the form of an oil.

¹H-NMR: δ (400 MHz; dms_o-d₆; 300°K): 6.7 (d, 1H, H pyrrole); 6.4 (d, 1H, H pyrrole);
5 5.0 (m, 1H, SiOCH₃); 4.2-3.75 (ABx, 2H, 2H dihydropyrrolizine); 3.3+2.8 (ABx, 2H, 2H dihydropyrrolizine); 3.70 (s, 3H, CO₂CH₃); 0.9 (s, 9H, ^tBu); 0.10 (ABx, 6H, SiMe₂)
IR: ν: -C=O (ester): 1701 cm⁻¹; SiCH₃: 1249 cm⁻¹; Si-O: 1118-1090 cm⁻¹; Si-C: 835-777 cm⁻¹

Step E: *Methyl (2R)-2-[[tert-butyl(dimethyl)silyl]oxy]-5-(5-fluoro-2-formylphenyl)-2,3-dihydro-1H-pyrrolizine-7-carboxylate*

The procedure is as in the process of Step C of Preparation 1, replacing 6-bromo-1,3-benzodioxole-5-carbaldehyde by 2-bromo-4-fluorobenzaldehyde.

Step F: *2-[(2R)-2-[[tert-Butyl(dimethyl)silyl]oxy]-7-(methoxycarbonyl)-2,3-dihydro-1H-pyrrolizin-5-yl]-4-fluorobenzoic acid*

The procedure is as in the process of Step D of Preparation 1.

Preparation 29: *4-Fluoro-2-[(2S)-2-hydroxy-7-(methoxycarbonyl)-2,3-dihydro-1H-pyrrolizin-5-yl]benzoic acid*

The procedure is as in the process of Preparation 28, replacing the methyl (4R)-4-hydroxy-L-prolinate used in Step A by methyl (4S)-4-hydroxy-L-prolinate.

Preparation 30: *4-Fluoro-2-[7-hydroxy-1-(methoxycarbonyl)-5,6,7,8-tetrahydro-indolizin-3-yl]benzoic acid*

The procedure is as in the process of Preparation 27, replacing the 2-bromo-4-fluorobenzaldehyde used in Step D by 6-bromo-1,3-benzodioxole-5-carbaldehyde.

Preparation 31: 6-[8-(Methoxycarbonyl)pyrrolo[1,2-a]pyrazin-6-yl]-1,3-benzodioxole-5-carboxylic acid

Step A: Methyl pyrrolo[1,2-a]pyrazine-8-carboxylate

To a solution of 10 g (65.7 mmol) of methyl pyrazin-2-ylacetate in 263 mL of anhydrous acetone (4 mL/mmol) there are added in succession 5.7 g of lithium bromide (65.7 mmol), 22.1 g of sodium bicarbonate (263 mmol) and then 9.4 mL of chloroacetaldehyde (50% solution in water) (72.6 mmoles). The whole is subsequently heated at reflux overnight. The reaction mixture is subsequently concentrated to dryness and then taken up in ethyl acetate. The organic phase is washed with a saturated sodium chloride solution, dried over magnesium sulphate, filtered and then concentrated to dryness. There is obtained an oil, which is purified by chromatography over silica gel (CH₂Cl₂/ethyl acetate gradient). After concentration, the title product is obtained in the form of a solid.

¹H-NMR: δ (400 MHz; dmso-d₆; 300°K): 9.36 (m, 1H, H pyrazine); 8.50 (dd, 1H, H pyrazine)); 7.8 (m, 2H, 1H pyrazine, 1H pyrrole); 7.31 (m, 1H, H pyrrole). 3.88 (s, 3H, OCH₃)

IR: v: -C=O (conjugated ester): 1686 cm⁻¹

Step B: 6-[8-(Methoxycarbonyl)pyrrolo[1,2-a]pyrazin-6-yl]-1,3-benzodioxole-5-carboxylic acid

The procedure is as in the processes of Steps C and D of Preparation 1.

Preparation 32 : 4-Fluoro-2-[1-(methoxycarbonyl)-3-indoliziny]benzoic acid

Methyl 1-indolizinecarboxylate is formed according to the process described in Steps A and B of Preparation 13. The title product is subsequently obtained according to the protocol described in Steps C and D of Preparation 1, replacing the 6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C by 2-bromo-4-fluorobenzaldehyde.

Preparation 1': (3S)-3-(4-Morpholinylmethyl)-1,2,3,4-tetrahydroisoquinoline

Step A: Benzyl (3S)-3-(4-morpholinylcarbonyl)-3,4-dihydro-2(1H)-isoquinoline carboxylate

To a solution of 5 g of (3S)-2-[(benzyloxy)carbonyl]-1,2,3,4-tetrahydro-3-isoquinoline-carboxylic acid (16 mmol) in 160 mL of dichloromethane there are added 1.5 mL of morpholine (17.6 mmol) and then 9 mL of *N,N,N*-triethylamine (64 mmol), 3.3 g of 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide (EDC) (19.2 mmol) and 2.6 g of hydroxybenzotriazole (HOBT) (19.2 mmol). The reaction mixture is stirred at ambient temperature overnight and is then poured onto a solution of ammonium chloride and extracted with ethyl acetate. The organic phase is subsequently dried over magnesium sulphate and then filtered and evaporated to dryness. The crude product so obtained is then purified by chromatography over silica gel (dichloromethane/methanol gradient). The product is obtained in the form of a foam.

¹H-NMR: δ (400 MHz; dmso-d₆; 353°K): 7.30 (m, 5H benzyl); 7.15 (m, 4H aromatic); 5.2-5.0 (m, 3H, 2H benzyl, 1H dihydroisoquinoline); 4.75-4.5 (2d, 2H dihydroisoquinoline); 3.55-3.3 (m, 8H morpholine); 3.15-2.9 (2dd, 2H dihydroisoquinoline)

IR: ν : >C=O: 1694;1650 cm⁻¹

Step B: Benzyl (3S)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinoline carboxylate

To a solution of 5.3 g of the product obtained in Step A (13.9 mmol) in 278 mL of tetrahydrofuran there are added 14 mL of BH₃Me₂S (27.8 mmol) at ambient temperature. The whole is heated for 4 hours at 80°C. It is allowed to return to ambient temperature, and then there are added 7 mL (14 mmol) of BH₃Me₂S. The reaction mixture is again heated at 80°C for 2 hours. The tetrahydrofuran is subsequently evaporated off, and there are then added slowly methanol and then 5.6 mL of 5N hydrochloric acid (27.8 mmol). The mixture is stirred at ambient temperature overnight and then at 80°C for one hour. There is subsequently added a saturated NaHCO₃ solution to the reaction mixture at 0°C until a pH of 8 is reached, and then extraction with ethyl acetate is carried out. The organic phase is

subsequently dried over magnesium sulphate and then filtered and evaporated to dryness. The title product is obtained in the form of an oil.

¹H-NMR: δ (400 MHz; dmso-d₆; 353°K): 7.43-7.30 (unresolved peak, 5H benzyl); 7.19 (m, 4H aromatic); 5.16 (m, 2H, 2H benzyl); 4.79-4.29 (d, 2H dihydroisoquinoline); 4.58 (m, 1H dihydroisoquinoline); 3.50 (m, 4H morpholine); 3.02-2.80 (dd, 2H dihydroisoquinoline); 2.42-2.28 (unresolved peak, 5H, 4H morpholine, 1H morpholine); 2.15 (dd, 1H morpholine)

IR: ν : >CH: 2810 cm⁻¹; ν : >C=O: 1694 cm⁻¹; ν : >C-O-C<: 1114 cm⁻¹; ν : >CH-Ar: 751; 697 cm⁻¹

Step C: (3S)-3-(4-Morpholinylmethyl)-1,2,3,4-tetrahydroisoquinoline

To a solution of 4.9 g of the compound of Step B (13.4 mmol) in 67 mL of ethanol there is added 0.980 g of palladium dihydroxide (20% by mass) at ambient temperature. The reaction mixture is placed under 1.2 bar of hydrogen at ambient temperature for 4 hours. It is subsequently passed over a Whatman filter, and then the palladium is rinsed several times with ethanol. The filtrate is evaporated to dryness. The title product is obtained in the form of an oil.

¹H-NMR: δ (400 MHz; dmso-d₆; 300°K): 7.12-7.0 (unresolved peak, 4H aromatic); 3.92 (s, 2H tetrahydroisoquinoline); 3.60 (t, 4H morpholine); 2.98 (m, 1H tetrahydroisoquinoline); 2.68 (dd, 1H tetrahydroisoquinoline); 2.5-2.3 (unresolved peak, 8H, 1H tetrahydroisoquinoline, 6H morpholine, 1H NH)

IR: ν : >NH: 3322 cm⁻¹; ν : >C-O-C<: 1115 cm⁻¹; ν : >CH-Ar: 742 cm⁻¹

Preparation 2': (3R)-3-(4-Morpholinylmethyl)-1,2,3,4-tetrahydroisoquinoline

The procedure is as in the process of Preparation 1', replacing the (3S)-2-[(benzyloxy)carbonyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid used in Step A by (3R)-2-[(benzyloxy)carbonyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid.

Preparation 3': (3*S*)-3-[(4-Methyl-1-piperazinyl)methyl]-1,2,3,4-tetrahydro-isoquinoline

The procedure is as in the process of Preparation 1', replacing the morpholine used in Step A by 1-methyl-piperazine.

5 **Preparation 4': (3*S*)-3-(1,4-Oxazepan-4-ylmethyl)-1,2,3,4-tetrahydroisoquinoline**

The procedure is as in the process of Preparation 1', replacing the morpholine used in Step A by 1,4-oxazepan.

Preparation 5': (3*S*)-3-[(3*R*)-3-Methylmorpholinyl]methyl}-1,2,3,4-tetrahydro-isoquinoline

10 The procedure is as in the process of Preparation 1', replacing the morpholine used in Step A by (3*R*)-3-methylmorpholine.

Preparation 6': (3*S*)-3-[(3*S*)-3-Methylmorpholinyl]methyl}-1,2,3,4-tetrahydro-isoquinoline

15 The procedure is as in the process of Preparation 1', replacing the morpholine used in Step A by (3*S*)-3-methylmorpholine.

Preparation 7': (3*S*)-3-[(3*S*,5*S*)-3,5-Dimethylmorpholinyl]methyl}-1,2,3,4-tetrahydro-isoquinoline

The procedure is as in the process of Preparation 1', replacing the morpholine used in Step A by (3*S*,5*S*)-3,5-dimethylmorpholine.

20 **Preparation 8': *N,N*-Dimethyl[(3*S*)-1,2,3,4-tetrahydro-3-isoquinolinyl]methanamine**

The procedure is as in the process of Preparation 1', replacing the morpholine used in Step A by *N,N*-dimethylamine.

Preparation 9': (3*S*)-3-{[4-(2-Methoxyethyl)piperazin-1-yl]methyl}-1,2,3,4-tetrahydroisoquinoline

25 The procedure is as in the process of Preparation 1', replacing the morpholine used in Step A by 1-(2-methoxyethyl)piperazine.

Preparation 10': 1-Methyl-4-[(3*S*)-1,2,3,4-tetrahydroisoquinolin-3-ylmethyl]-piperazin-2-one

The procedure is as in the process of Preparation 1', replacing the morpholine used in Step A by 1-methylpiperazin-2-one.

5 **Preparation 11': 2-Methoxy-*N*-methyl-*N*-[(3*S*)-1,2,3,4-tetrahydroisoquinolin-3-ylmethyl]ethanamine**

The procedure is as in the process of Preparation 1', replacing the morpholine used in Step A by 2-methoxy-*N*-methylethanamine.

10 **Preparation 12': *N*-Ethyl-2-methoxy-*N*-[(3*S*)-1,2,3,4-tetrahydroisoquinolin-3-ylmethyl]ethanamine**

The procedure is as in the process of Preparation 1', replacing the morpholine used in Step A by *N*-ethyl-2-methoxyethanamine.

15 **Preparation 13': (3*S*)-3-{[4-(Methylsulphonyl)piperazin-1-yl]methyl}-1,2,3,4-tetrahydroisoquinoline**

The procedure is as in the process of Preparation 1', replacing the morpholine used in Step A by 1-(methylsulphonyl)piperazine.

Preparation 14': (3*S*)-3-{[4-(2,2,2-Trifluoroethyl)piperazin-1-yl]methyl}-1,2,3,4-tetrahydroisoquinoline

20 The procedure is as in the process of Preparation 1', replacing the morpholine used in Step A by 1-(2,2,2-trifluoroethyl)piperazine.

Preparation 15': (3*S*)-3-[(1,1-dioxidothiomorpholin-4-yl)methyl]-1,2,3,4-tetrahydroisoquinoline

The procedure is as in the process of Preparation 1', replacing the morpholine used in Step A by thiomorpholine 1,1-dioxide.

Preparation 16' : (3*S*)-3-[(3-Methoxypyrrolidin-1-yl)methyl]-1,2,3,4-tetrahydroisoquinoline

The procedure is as in the process of Preparation 1', replacing the morpholine used in Step A by 3-methoxypyrrolidine.

5 **Preparation 17' :** (3*S*)-3-[(3,3-Difluoropyrrolidin-1-yl)methyl]-1,2,3,4-tetrahydroisoquinoline

The procedure is as in the process of Preparation 1', replacing the morpholine used in Step A by 3,3-difluoropyrrolidine.

10 **Preparation 18' :** (3*S*)-3-[(3-methoxyazetidin-1-yl)methyl]-1,2,3,4-tetrahydroisoquinoline

The procedure is as in the process of Preparation 1', replacing the morpholine used in Step A by 3-methoxyazetidine.

15 **Preparation 19' :** (3*S*)-3-[(3-fluoroazetidin-1-yl)methyl]-1,2,3,4-tetrahydroisoquinoline

The procedure is as in the process of Preparation 1', replacing the morpholine used in Step A by 3-fluoroazetidine.

Preparation 1'': 4-[[*tert*-Butyl(dimethyl)silyl]oxy]-*N*-phenylaniline

20 To a solution of 12 g of 4-anilinophenol (64.7 mmol) in 200 mL of acetonitrile there are added at ambient temperature 6.7 g of imidazole (97.05 mmol) and 11.7 g of *tert*-butyl(chloro)dimethylsilane (77.64 mmol). The whole is stirred at 70°C for 4 hours. Then the reaction mixture is poured onto water and extracted with ether. The organic phase is subsequently dried over magnesium sulphate and then filtered and evaporated to dryness. The crude product so obtained is then purified by chromatography over silica gel (petroleum ether/dichloromethane gradient). The title product is obtained in the form of a powder.

25

¹H-NMR: δ (400 MHz; dmso-d₆; 300°K): 7.84 (s, 1H NH); 7.17 (t, 2H aniline); 6.98 (d, 2H phenoxy); 6.94 (d, 2H aniline); 6.76 (d, 2H phenoxy); 6.72(t, 1H aniline); 0.95 (s, 9H *tert*-butyl); 0.15 (s, 6H dimethyl)

IR: v: >NH: 3403 cm⁻¹; >Ar: 1597 cm⁻¹

5 The amines NHR₃R₄ wherein R₃ and R₄ independently of one another represent an aryl or heteroaryl group are prepared according to known procedures described in the literature (Surry D.S et al., Chemical Science, 2011, 2, 27-50, Charles M.D. et al., Organic Letters, 2005, 7, 3965-3968). The reaction of protection of the hydroxy function of the 4-anilinophenol described in Preparation 1" can be applied to various secondary amines
10 NHR₃R₄ (as defined hereinbefore) having one or more hydroxy functions, when they are available commercially. Alternatively, the secondary amines having at least one hydroxy substituent may be synthesised directly in a protected form, i.e. starting from reagents whose hydroxy function has been protected beforehand. Among the protecting groups, *tert*-butylsilyloxy and benzyloxy are especially preferred.

15 Among the amines NHR₃R₄ having a hydroxy substituent that are used for synthesising the compounds of the invention there may be mentioned: 4-(4-toluidino)phenol, 4-(4-chloroanilino)phenol, 4-(3-fluoro-4-methylanilino)phenol, 4-[4-(trifluoromethoxy)anilino]-phenol, 4-[4-hydroxyanilino]phenol, {4-[(1-methyl-1*H*-indol-6-yl)amino]phenyl}-methanol, 4-(2,3-dihydro-1*H*-indol-6-ylamino)phenol, 4-[(1-methyl-2,3-dihydro-1*H*-indol-6-yl)amino]phenol, 4-[(1-methyl-1*H*-indol-6-yl)amino]phenol, 4-[(1-methyl-1*H*-indol-6-yl)amino]cyclohexanol, 4-[(1-methyl-1,2,3,4-tetrahydro-6-quinoliny)amino]phenol, 4-[(4-methyl-3,4-dihydro-2*H*-1,4-benzoxazin-7-yl)amino]phenol, 4-[4-(diethylamino)anilino]-phenol, 4-(2,3-dihydro-1*H*-inden-5-ylamino)phenol, 4-[(1-methyl-1*H*-indazol-5-yl)amino]-phenol, 4-[(1'-methyl-1',2'-dihydrospiro[cyclopropane-1,3'-indol]-5'-yl)amino]phenol, 4-
25 [(1,3,3-trimethyl-2,3-dihydro-1*H*-indol-5-yl)amino]phenol, 4-[4-methoxy-3-(trifluoromethyl)anilino]phenol, 4-[4-(methylsulphanyl)-3-(trifluoromethyl)anilino]phenol, 2-fluoro-4-[(1-methyl-1*H*-indol-5-yl)amino]phenol, 4-[(1-ethyl-1*H*-indol-5-yl)amino]phenol, 4-[(1-ethyl-2,3-dihydro-1*H*-indol-5-yl)amino]phenol, 4-[(1-isopropyl-2,3-dihydro-1*H*-indol-5-yl)amino]phenol, 4-(butylamino)phenol, 3-[(1-methyl-1*H*-indol-5-yl)amino]-1-propanol, 4-[(1-methyl-1*H*-indol-5-yl)amino]-1-butanol, 4-[(3-fluoro-4-methylphenyl)amino]phenol, 4-[(3-chloro-4-methylphenyl)amino]phenol, 4-[(4-fluorophenyl)amino]-

phenol, 4-[(1-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)amino]phenol, 4-[(4-fluorophenyl)-amino]phenol, 4-[(2-fluorophenyl)amino]phenol, 4-[(3-fluorophenyl)amino]phenol, 4-[(2,4-difluorophenyl)amino]phenol, 4-[(3,4-difluorophenyl)amino]phenol, 3-[(4-hydroxyphenyl)amino]benzonitrile, 4-[(3-methoxyphenyl)amino]phenol, 4-[(3,5-difluorophenyl)-amino]phenol, 4-[(3-methylphenyl)amino]phenol, 4-[(4-hydroxyphenyl)amino]benzo-
nitrile, 4-[(3-chlorophenyl)amino]phenol, 4-(pyrimidin-2-ylamino)phenol, 4-[(cyclobutylmethyl)amino]phenol, 2-[(4-hydroxyphenyl)amino]benzonitrile, 4-[[1-methyl-1*H*-pyrazol-4-yl)methyl]amino}phenol, 4-[(cyclopropylmethyl)amino]phenol, 4-[[1-methyl-1*H*-pyrazol-3-yl)methyl]amino}phenol, 4-(but-2-yn-1-ylamino)phenol, 4-(pyrazin-2-ylamino)phenol, 4-(pyridin-2-ylamino)phenol, 4-(pyridazin-3-ylamino)phenol, 4-(pyrimidin-5-ylamino)phenol, 4-(pyridin-3-ylamino)phenol, 4-[(3,5-difluoro-4-methoxyphenyl)-amino]phenol, 4-(pyridin-4-ylamino)phenol, 4-[(3-fluoro-4-methoxyphenyl)amino]phenol, 2-(phenylamino)pyrimidin-5-ol, 5-[(4-hydroxyphenyl)amino]-2-methoxybenzonitrile, 4-[[3-(trifluoromethyl)phenyl]amino}phenol.

The hydroxy function(s) of the secondary amines listed above is (are) protected beforehand by a suitable protecting group prior to coupling to an acid derivative of the compound of formula (VII) as defined in the preceding general process.

Example 1: *N*-(4-Hydroxyphenyl)-3-{6-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl]carbonyl]-1,3-benzodioxol-5-yl]}-*N*-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

Step A: Methyl 3-{6-[[[(3*S*)-3-(4-Morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl]carbonyl]-1,3-benzodioxol-5-yl]}-5,6,7,8-tetrahydro-1-indolizinecarboxylate

To a solution of 2 g of the compound of Preparation 1 in 20 mL of dichloromethane there are added at ambient temperature 5.5 mL of *N,N,N*-triethylamine (6.96 mmol), 2.12 g of the compound of Preparation 1' (6.96 mmol), and then 0.94 g of hydroxybenzotriazole (HOBT) and 1.34 g of 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide (EDC) (6.96 mmol). The reaction mixture is subsequently stirred at ambient temperature overnight, and is then poured onto an ammonium chloride solution and extracted with ethyl acetate. The organic phase is subsequently dried over magnesium sulphate and then filtered and evaporated to dryness. The crude product so obtained is then purified by

chromatography over silica gel (heptane/AcOEt gradient). The title product is obtained in the form of an oil.

¹H-NMR: δ (500 MHz; dms_o-d₆; 300°K): 7.2-6.9 (m, 4H, H aromatic); 7.04-7.03-7.00 (m, 1H, H aromatic); 6.85 (m, 1H, H aromatic); 6.35-6.26-6.06 (m, 1H, H tetrahydroindolizine); 6.15-6.12 (m, 2H, H methylenedioxy); 5.06-4.84 (m, 1H, H dihydroisoquinoline); 4.86-4.17 (m, 2H, H dihydroisoquinoline); 3.65-3.6-3.55 (m, 3H, H methyl ester); 3.43-4.26 (m, 2H, H tetrahydroindolizine); 3.58-3.5 (m, 4H, H morpholine); 2.37-3.05 (m, 4H, 2H dihydroisoquinoline, 2H tetrahydroindolizine); 1.68-2.56 (m, 4H, H morpholine); 1.4-2.0 (m, 4H, H tetrahydroindolizine)

IR: ν : >C=O 1695 cm⁻¹ ester; ν : >C=O 1625 cm⁻¹ amide; ν : >C-O-C< 1214-1176-1115 cm⁻¹; >CH-Ar 772-744 cm⁻¹

Step B: *Lithium 3-[6-[(3S)-3-(morpholinomethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]-1,3-benzodioxol-5-yl]-5,6,7,8-tetrahydro-1-indolizinecarboxylate*

To a solution of 4.6 g of the compound of Step A (8.26 mmol) in 24 mL of dioxane there is added a solution of lithium hydroxide (675 mg, 16.1 mmol). The whole is placed in a 140 W microwave oven at 100°C for a period of 2.5 hours. The reaction mixture is subsequently filtered and dried. The solid so obtained is dried at 40°C in a hot cabinet in the presence of P₂O₅.

¹H-NMR: δ (400 MHz; dms_o-d₆; 353°K): 6.7-7.15 (unresolved peak, 6H, H aromatic); 6.21 (s, 1H, H aromatic); 6.03 (s, 2H, H methylenedioxy); 4.0-5.0 (unresolved peak, 3H dihydroisoquinoline); 3.4-3.6 (unresolved peak, 3H tetrahydroindolizine, 3H morpholine); 2.5-3.1 (unresolved peak, 4H, 2H tetrahydroindolizine, 2H morpholine); 1.5-2.4 (unresolved peak, 10H morpholine)

IR: ν :>C=O 1567 broad cm⁻¹ acetate; ν : 1236 cm⁻¹

Step C: *N-(4-[[tert-Butyl(dimethyl)silyl]oxy]phenyl)-3-{6-[[((3S)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl]-N-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide*

To a solution of 2.6 g of the compound of Step B (4.73 mmol) in 47 mL of dichloromethane there are added, dropwise, 1.2 mL of oxalyl chloride at 0°C. The reaction mixture is stirred at ambient temperature for 11 hours, and then co-evaporated several times with dichloromethane. The product so obtained is suspended in 37 mL of dichloromethane and is then added to a solution of 2.1 g of the compound obtained in Preparation 1" (7.1 mmol) in 10 mL of dichloromethane in the presence of 0.6 mL of pyridine (7.1 mmol). The whole is stirred at ambient temperature overnight. The reaction mixture is concentrated and purified by chromatography over silica gel (dichloromethane/methanol gradient). The title product is obtained in the form of a foam.

¹H-NMR: δ (500MHz; dms_o-d₆; 300°K): 6.9-7.3 (9H aromatic); 6.88 (2H aromatic); 6.72-6.87 (2H aromatic); 6.64 (2H aromatic); 6.13 (2H methylenedioxy); 5.05-4.74 (1H dihydroisoquinoline); 4.25-4.13 (2H dihydroisoquinoline); 3.44-3.7 (4H morpholine); 3.62-3.52 (2H tetrahydroindolizine); 3.0-2.6 (4H, 2H tetrahydroindolizine, 2H dihydroisoquinoline); 2.54-1.94 (6H morpholine); 1.91-1.53 (4H tetrahydroindolizine); 0.92 (9H *tert*-butyl); 0.17 (6H dimethyl)

IR: ν :>C=O: 1632 cm⁻¹; ν : >C-O-C<: 1237 cm⁻¹; ν : -Si-O-C-: 1035 cm⁻¹; -Si-C-: 910 cm⁻¹; >CH-Ar: 806 cm⁻¹

Step D: *N-(4-Hydroxyphenyl)-3-{6-[[((3S)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl]-N-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride*

To a solution of 1.9 g of the compound obtained in Step C (2.3 mmol) in 4 mL of methanol there is added 0.646 g (11.5 mmol) of potassium hydroxide dissolved in 8 mL of methanol. The whole is stirred at ambient temperature for 30 minutes. The reaction mixture is subsequently diluted in dichloromethane and washed in succession with a 1N HCl solution, a saturated NaHCO₃ solution and then a saturated NaCl solution until a neutral pH is reached. The organic phase is subsequently dried over magnesium sulphate, filtered and evaporated. The crude product so obtained is purified on silica gel (dichloro-

methane/methanol gradient). The solid is subsequently dissolved in dichloromethane, and 2 mL of 1N ethereal hydrogen chloride are added. The whole is stirred for one hour and then evaporated to dryness. The hydrochloride so obtained is dissolved in a water/acetonitrile mixture until completely dissolved and is then lyophilised.

5 **Elemental microanalysis:**

	%C	%H	%N	%Cl
<i>Calculated</i>	69.11	5.8	7.5	4.74
<i>Found</i>	68.95	5.46	7.51	4.48

Rotatory power: (α)_D²⁰ = + 50.8° (c = 9 mg/mL, MeOH)

10 **Example 2:** *N*-(4-Hydroxyphenyl)-*N*-(4-methylphenyl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl]-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1" used in Step C by 4-[[*tert*-butyl(dimethyl)silyl]oxy]-*N*-(4-methylphenyl)aniline.

15 **Elemental microanalysis:**

	%C	%H	%N	%Cl	%Cl
<i>Calculated</i>	69.42	5.96	7.36	4.66	4.66
<i>Found</i>	69.19	5.76	7.19	4.62	4.48

20 **Example 3:** *N*-(4-Chlorophenyl)-*N*-(4-hydroxyphenyl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl]-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1" used in Step C by 4-[[*tert*-butyl(dimethyl)silyl]oxy]-*N*-(4-chlorophenyl)aniline.

Elemental microanalysis:

	%C	%H	%N	%Cl	%Cl ⁻
Calculated	66.07	5.42	7.17	9.07	4.54
Found	65.74	5.14	7.08	9.02	4.48

5 **Rotatory power:** (α)_D²⁰ = + 80.9° (c = 2.5 mg/mL, MeOH)

Example 4: *N*-(3-Fluoro-4-methylphenyl)-*N*-(4-hydroxyphenyl)-3-{6-[(*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(*1H*)-isoquinoliny)carbonyl]-1,3-benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

10 The procedure is as in the process of Example 1, replacing the compound of Preparation 1" used in Step C by 4-{{*tert*-butyl(dimethyl)silyl}oxy}-*N*-(3-fluoro-4-methylphenyl)aniline.

High-resolution mass (ESI+):

Empirical formula: C₄₄H₄₃FN₄O₆

[M+H]⁺ calculated: 743.3245

[M+H]⁺ measured: 743.3250

15 **Rotatory power:** (α)_D²⁰ = + 40.7° (c = 2.5 mg/mL, MeOH)

Example 5: *N*-(4-Hydroxyphenyl)-3-{6-[(*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(*1H*)-isoquinoliny)carbonyl]-1,3-benzodioxol-5-yl}-*N*-[4-(trifluoromethoxy)phenyl]-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

20 The procedure is as in the process of Example 1, replacing the compound of Preparation 1" used in Step C by 4-{{*tert*-butyl(dimethyl)silyl}oxy}-*N*-(4-trifluoromethoxyphenyl)aniline.

Elemental microanalysis:

	%C	%H	%N	%Cl-
Calculated	63.57	5.09	6.74	4.26
Found	63.38	4.95	6.88	4.23

Example 6: *N,N*-bis(4-Hydroxyphenyl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl]-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1" used in Step C by 4-{{*tert*-butyl(dimethyl)silyl}oxy}-*N*-(4-{{*tert*-butyl(dimethyl)silyl}oxy}phenyl)aniline.

Elemental microanalysis:

	%C	%H	%N	%Cl-
Calculated	67.66	5.68	7.34	4.64
10 Found	67.11	5.49	7.31	4.74

Rotatory power: $(\alpha)_D^{20} = + 50.8^\circ$ (c = 6 mg/mL, MeOH)

Example 7: *N*-[4-(Hydroxymethyl)phenyl]-*N*-(1-methyl-1*H*-indol-5-yl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl]-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1" used in Step C by *N*-[4-({*tert*-butyl(dimethyl)silyl}oxy)methyl]phenyl]-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
20 Calculated	69.32	5.94	8.6	4.35
Found	69.63	5.75	8.59	4.13

Example 8: *N*-(2,3-Dihydro-1*H*-indol-5-yl)-*N*-[4-(hydroxy)phenyl]-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide bis(hydrochloride)

The procedure is as in the process of Example 1, replacing the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-5-indolinamine.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	65.53	5.74	8.49	8.60
Found	65.47	5.69	8.43	7.82

Rotatory power: $(\alpha)_D^{20} = +40.9^\circ$ ($c = 3.5$ mg/mL, MeOH)

Example 9: *N*-[4-(Hydroxy)phenyl]-*N*-(1-methyl-2,3-dihydro-1*H*-indol-5-yl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-5-indolinamine.

High-resolution mass (ESI+):

Empirical formula: C₄₆H₄₇N₅O₆

[M+H]⁺ calculated: 766.3605

[M+H]⁺ measured: 766.3601

Example 10: *N*-[4-(Hydroxy)phenyl]-*N*-(1-methyl-1*H*-indol-5-yl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-

amine.

Elemental microanalysis: (theory for 1.1 HCl)

	%C	%H	%N	%Cl
Calculated	68.72	5.78	8.71	4.85
5 Found	68.39	5.55	8.66	4.33

Rotatory power: $(\alpha)_D^{20} = + 37.6^\circ$ (c = 7 mg/mL, MeOH)

Example 11: *N*-(4-Hydroxyphenyl)-3-{6-[[((3*R*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl]-*N*-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

10 The procedure is as in the process of Example 1, replacing the compound of Preparation 1' used in Step A by the compound of Preparation 2'.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	69.11	5.80	7.50	4.74
15 Found	68.89	5.23	7.41	4.62

Rotatory power: $(\alpha)_D^{20} = - 45.1^\circ$ (c = 9 mg/mL, MeOH)

Example 12: *N*-(4-Hydroxycyclohexyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl]-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

20 The procedure is as in the process of Example 1, replacing the compound of Preparation 1'' used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}cyclohexyl)-1-methyl-1*H*-indol-5-amine.

High-resolution mass (ESI+):

Empirical formula: C₄₆H₅₁N₅O₆

[M+H]⁺ calculated: 770.3918

[M+H]⁺ measured: 770.3928

Example 13: N-(4-Hydroxyphenyl)-N-(1-methyl-1*H*-indol-5-yl)-3-{6-[[[(3*S*)-3-[(4-methyl-1-piperazinyl)methyl]-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl]-5,6,7,8-tetrahydro-1-indolizine carboxamide bis(hydrochloride)

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1' used in Step A by the compound of Preparation 3', and on the other hand the compound of Preparation 1'' used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl	%Cl ⁻
Calculated	66.43	5.93	9.89	8.34	8.34
Found	66.36	5.79	9.83	8.11	7.67

Rotatory power: (α)_D²⁰ = + 60.1° (c = 6 mg/mL, MeOH)

Example 14: N-(4-Hydroxyphenyl)-N-(1-methyl-1*H*-indol-5-yl)-3-{6-[[[(3*S*)-3-(1,4-oxazepan-4-ylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl]-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1' used in Step A by the compound of Preparation 4', and on the other hand the compound of Preparation 1'' used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl	%CL
<i>Calculated</i>	69.32	5.94	8.60	4.35	4.35
<i>Found</i>	69.24	5.56	8.52	4.47	4.44

5 **Example 15:** *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-{6-[[((3*S*)-3-[[((3*R*)-3-methylmorpholinyl)methyl]-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl]-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1' used in Step A by the compound of Preparation 5', and on the other hand
10 the compound of Preparation 1'' used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
<i>Calculated</i>	69.32	5.94	8.60	4.35
15 <i>Found</i>	69.10	5.68	8.52	4.29

Example 16: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-{6-[[((3*S*)-3-[[((3*S*)-3-methylmorpholinyl)methyl]-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl]-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound
20 of Preparation 1' used in Step A by the compound of Preparation 6', and on the other hand the compound of Preparation 1'' used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
25 <i>Calculated</i>	69.32	5.94	8.60	4.35
<i>Found</i>	68.97	5.55	8.44	3.73

Example 17: 3-{6-[[[(3*S*)-3-[[[(3*S*,5*S*)-3,5-Dimethylmorpholinyl]methyl]-3,4-dihydro-2(1*H*)-isoquinolinyl]carbonyl]-1,3-benzodioxol-5-yl]-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1' used in Step A by the compound of Preparation 7', and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
10 <i>Calculated</i>	69.59	6.08	8.45	4.28
<i>Found</i>	69.29	5.52	8.46	4.09

Example 18: 3-{5-Bromo-2-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 2, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

High-resolution mass (ESI+):

Empirical formula: C₄₅H₄₄⁷⁹BrN₅O₄

[M+H]⁺ calculated: 798.2655

[M+H]⁺ measured: 798.2626

Example 19: 3-{5-Bromo-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-2,3-dihydro-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 2, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-1-methyl-5-indolinamine.

High-resolution mass (ESI+):

Empirical formula: C₄₅H₄₆⁷⁹BrN₅O₄

[M+H]⁺ calculated: 800.2811

[M+H]⁺ measured: 800.2791

Example 20: 3-{5-Chloro-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1 used in Step A by the compound of Preparation 3.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	68.38	5.74	7.59	4.81
Found	67.89	5.71	7.72	4.68

Rotatory power: (α)_D²⁰ = + 53.7° (c = 6 mg/mL, MeOH)

Example 21: 3-{5-Chloro-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(2,3-dihydro-1*H*-indol-5-yl)-*N*-(4-hydroxyphenyl)-5,6,7,8-tetrahydro-1-indolizine carboxamide bis(hydrochloride)

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-5-indolinamine.

High-resolution mass (ESI+):

Empirical formula: C₄₄H₄₄³⁵ClN₅O₄

[M+H]⁺ calculated: 742.3160

[M+H]⁺ measured: 742.3120

Example 22: 3-{5-Chloro-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	68.04	5.72	8.82	4.91
Found	67.84	5.46	8.64	5.21

Rotatory power: (α)_D²⁰ = + 55.9° (c = 7 mg/mL, MeOH)

Example 23: 3-{5-Chloro-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-2,3-dihydro-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide bis(hydrochloride)

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-1-methyl-5-indolinamine.

Elemental microanalysis:

	%C	%H	%N	%Cl	%Cl
10 <i>Calculated</i>	65.18	5.83	8.45	12.83	8.55
<i>Found</i>	65.75	5.45	8.39	11.71	7.54

Rotatory power: (α)_D²⁰ = + 56.6° (c = 6 mg/mL, MeOH)

Example 24: 3-{5-Fluoro-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 4, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
20 <i>Calculated</i>	69.80	5.86	9.04	4.58
<i>Found</i>	69.57	5.62	8.76	4.47

Rotatory power: (α)_D²⁰ = + 55.0° (c = 5 mg/mL, MeOH)

Example 25: 3-{5-Fluoro-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1 used in Step A by the compound of Preparation 4.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	69.94	5.87	7.77	4.92
Found	69.70	5.32	7.72	4.80

Example 26: 3-{5-Chloro-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1,2,3,4-tetrahydro-6-quinoliny)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1,2,3,4-tetrahydro-6-quinolinamine.

Elemental microanalysis: (theory for 1.5 HCl)

	%C	%H	%N	%Cl
Calculated	66.97	6.05	8.49	6.45
Found	66.80	5.55	8.32	6.23

Example 27: 3-{5-Chloro-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(4-methyl-3,4-dihydro-2*H*-1,4-benzoxazin-7-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand

the compound of Preparation 1" used in Step C by *N*-(4-([*tert*-butyl(dimethyl)silyl]oxy)phenyl)-4-methyl-3,4-dihydro-2*H*-1,4-benzoxazin-7-amine.

Elemental microanalysis: (theory for 1.1 HCl)

	%C	%H	%N	%Cl
5 <i>Calculated</i>	66.53	5.84	8.62	4.80
<i>Found</i>	66.59	5.39	8.47	4.80

Example 28: 3-{5-Chloro-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-[4-(diethylamino)phenyl]-*N*-(4-hydroxyphenyl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

10 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*¹-(4-([*tert*-butyl(dimethyl)silyl]oxy)phenyl)-*N*⁴,*N*⁴-diethyl-1,4-benzenediamine.

Elemental microanalysis: (theory for 1.6 HCl)

	%C	%H	%N	%Cl
15 <i>Calculated</i>	66.51	6.26	8.43	6.83
<i>Found</i>	66.71	5.58	8.39	7.08

Example 29: 3-{5-Chloro-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(2,3-dihydro-1*H*-inden-5-yl)-*N*-(4-hydroxyphenyl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

20

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-([*tert*-butyl(dimethyl)silyl]oxy)phenyl)-5-indanamine.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	69.49	5.96	7.20	4.56
Found	69.47	5.43	7.21	4.21

5 **Example 30:** 3-{5-Chloro-2-[(3*S*)-3-[(4-methyl-1-piperazinyl)methyl]-3,4-dihydro-2(1*H*)-isoquinolinyl]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide bis(hydrochloride)

10 The procedure is as in the process of Example 1, replacing on the one hand the compounds of Preparations 1 and 1' used in Step A by the respective compounds of Preparations 3 and 3', and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

High-resolution mass (ESI+):

Empirical formula: C₄₆H₄₇³⁵ClN₆O₃

[M+H]⁺ calculated: 767.3476

15 [M+H]⁺ measured: 767.3476

Example 31: *N*-(4-Hydroxyphenyl)-3-{8-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl]carbonyl]-3,4-dihydro-2*H*-1,5-benzodioxepin-7-yl}-*N*-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

20 The procedure is as in the process of Example 1, replacing the compound of Preparation 1 used in Step A by the compound of Preparation 5.

High-resolution mass (ESI+):

Empirical formula: C₄₅H₄₆N₄O₆

[M+H]⁺ calculated: 739.3496

[M+H]⁺ measured: 739.3479

Example 32: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-{8-[(*(3S)*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-3,4-dihydro-2*H*-1,5-benzodioxepin-7-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 5, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
10 <i>Calculated</i>	69.59	6.08	8.45	4.78
<i>Found</i>	69.23	5.46	8.41	4.16

Example 33: *N*-(4-Hydroxyphenyl)-3-{5-methoxy-2-[(*(3S)*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 6, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
20 <i>Calculated</i>	70.26	6.15	8.91	4.51
<i>Found</i>	69.78	5.36	8.90	4.29

Rotatory power: $(\alpha)_D^{20} = +42.1^\circ$ (c = 6 mg/mL, MeOH)

Example 34: *N*-(4-Hydroxyphenyl)-3-{7-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-2,3-dihydro-1,4-benzodioxin-6-yl]-*N*-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1 used in Step A by the compound of Preparation 7.

Elemental microanalysis:

	%C	%H	%N	%Cl
<i>Calculated</i>	69.42	5.96	7.36	4.66
<i>Found</i>	69.39	5.56	7.30	4.49

Rotatory power: $(\alpha)_D^{20} = +34.5^\circ$ (c = 6 mg/mL, MeOH)

Example 35: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-{7-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-2,3-dihydro-1,4-benzodioxin-6-yl]-5,6,7,8-tetrahydro-1-indolizine carboxamide

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 7, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-1-methyl-1*H*-indol-5-amine, it being understood that the product so obtained is not subjected to a step of salt formation in the presence of ethereal hydrogen chloride.

Elemental microanalysis:

	%C	%H	%N
<i>Calculated</i>	72.57	6.09	9.00
<i>Found</i>	73.11	5.70	8.95

Rotatory power: $(\alpha)_D^{20} = +88.2^\circ$ (c = 7 mg/mL, MeOH)

Example 36: 3-{5-Ethoxy-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 8, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
10 Calculated	70.53	6.30	8.75	4.43
Found	70.77	5.59	8.66	4.22

Example 37: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-{2,2-dideuterio-6-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 9, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-1-methyl-1*H*-indol-5-amine.

High-resolution mass (ESI+):

Empirical formula: C₄₆H₄₃N₅O₆D₂

[M+H]⁺ calculated: 766.3573

[M+H]⁺ measured: 766.3533

Rotatory power: (α)_D²⁰ = + 35.5° (c = 3.5 mg/mL, MeOH)

Example 38: *N*-(4-Hydroxyphenyl)-3-{2,2-dideuterio-6-[(*(3S)*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(*1H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl]-*N*-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

Step A: *N*-(4-Hydroxyphenyl)-3-{2,2-dideuterio-6-[(*(3S)*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(*1H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl]-*N*-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide

The procedure is as in the process of Example 1, replacing the compound of Preparation 1 used in Step A by the compound of Preparation 9, it being understood that the step of salt formation in the presence of ethereal hydrogen chloride is carried out only in the following Step B.

Step B: *N*-(4-Hydroxyphenyl)-3-{2,2-dideuterio-6-[(*(3S)*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(*1H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl]-*N*-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The product obtained in Step A is dissolved in dichloromethane, and 2 mL of 1N ethereal hydrogen chloride are added. The whole is stirred for one hour and then evaporated to dryness. The hydrochloride so obtained is dissolved in a water/acetonitrile mixture until completely dissolved, and is then lyophilised.

Elemental microanalysis:

	%C	%H	%N	%Cl	%Cl ⁻
Calculated	68.93	5.80	7.48	4.73	4.73
Found	68.45	5.49	7.57	4.63	4.54

Example 39: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indazol-5-yl)-3-{7-[(*(3S)*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(*1H*)-isoquinoliny]carbonyl]-2,3-dihydro-1,4-benzodioxin-6-yl]-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 7, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-

butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indazol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	67.76	5.81	10.31	4.35
5 Found	67.82	5.25	9.87	4.18

Rotatory power: (α)_D²⁰ = + 42.6° (c = 5 mg/mL, MeOH)

Example 40: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1,2,3,4-tetrahydro-6-quinolinyl)-3-{7-
[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl]carbonyl]-2,3-
dihydro-1,4-benzodioxin-6-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide
10 hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 7, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1,2,3,4-tetrahydro-6-quinolinamine.

Elemental microanalysis:

	%C	%H	%N	%Cl	%Cl
Calculated	66.51	6.16	8.08	8.18	8.18
15 Found	66.85	5.88	8.04	6.47	6.25

Example 41: *N*-(4-Hydroxyphenyl)-*N*-(4-methyl-3,4-dihydro-2*H*-1,4-benzoxazin-7-yl)-
20 3-{7-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl]carbonyl]-2,3-
dihydro-1,4-benzodioxin-6-yl]-5,6,7,8-tetrahydro-1-indolizine carboxamide
hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 7, and on the other hand
25 the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-

butyl(dimethyl)silyl]oxy}phenyl)-4-methyl-3,4-dihydro-2*H*-1,4-benzoxazin-7-amine.

High-resolution mass (ESI+):

Empirical formula: C₄₇H₄₉N₅O₇

[M+H]⁺ calculated: 796.3710

5 [M+H]⁺ measured: 796.3687

Example 42: 3-{5-Chloro-2-(((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny)carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indazol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

10 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indazol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl	%Cl ⁻
15 Calculated	66.75	5.60	10.61	8.96	4.48
Found	66.63	5.06	10.42	8.83	4.46

Example 43: 1-{5-Chloro-2-(((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny)carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-2,3-dihydro-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-3-indolizine carboxamide hydrochloride

20 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 24, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
<i>Calculated</i>	68.35	5.74	8.86	8.97
<i>Found</i>	68.29	5.21	8.76	9.04

5 **Example 44:** 3-{5-Fluoro-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indazol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

10 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 4, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indazol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
<i>Calculated</i>	68.16	5.72	10.84	4.57
15 <i>Found</i>	67.93	5.01	10.89	4.24

Example 45: 3-{5-Chloro-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1'-methyl-1',2'-dihydrospiro[cyclopropane-1,3'-indol]-5'-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide

20 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-(1'-methyl-1',2'-dihydrospiro[cyclopropane-1,3'-indol]-5'-yl)amine.

Elemental microanalysis:

	%C	%H	%N
<i>Calculated</i>	72.15	6.18	8.95
<i>Found</i>	71.86	5.76	8.85

5 **Example 46:** 3-{5-Chloro-2-[[((3*S*)-3-(1,4-oxazepan-4-ylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

10 The procedure is as in the process of Example 1, replacing on the one hand the compounds of Preparations 1 and 1' used in Step A by the respective compounds of Preparations 3 and 4', and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N
<i>Calculated</i>	68.65	5.89	8.70
15 <i>Found</i>	68.33	5.45	8.54

Rotatory power: (α)_D²⁰ = + 13.6° (c = 4 mg/mL, MeOH)

Example 47: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-[2-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-5-(trifluoromethyl)-phenyl]-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

20 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 10, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
<i>Calculated</i>	67.02	5.50	8.50	4.30
<i>Found</i>	67.01	5.11	8.47	4.21

5 **Example 48:** *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-[2-(((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny)carbonyl]-5-(trifluoromethoxy)-phenyl]-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 11, and on the other hand
10 the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl	%Cl
<i>Calculated</i>	65.75	5.40	8.33	4.22	4.22
15 <i>Found</i>	65.78	5.00	8.35	4.33	4.50

Example 49: 3-{5-Chloro-2-(((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny)carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1,3,3-trimethyl-2,3-dihydro-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand
20 the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1,3,3-trimethyl-5-indolinamine, it being understood that the product so obtained is not subjected to a step of salt formation in the presence of ethereal hydrogen chloride.

Elemental microanalysis:

	%C	%H	%N
<i>Calculated</i>	71.97	6.42	8.93
<i>Found</i>	71.87	6.22	8.94

5 **Example 50:** *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indazol-5-yl)-3-{2,2-dideuterio-6-
 [((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-
 benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound
 of Preparation 1 used in Step A by the compound of Preparation 9, and on the other hand
 10 the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-
 butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indazol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
<i>Calculated</i>	67.28	5.66	10.46	4.41
15 <i>Found</i>	66.77	5.07	10.25	3.92

Example 51: *N*-(3-Fluoro-4-methylphenyl)-*N*-(4-hydroxyphenyl)-3-{2,2-dideuterio-6-
 [((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-
 benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound
 20 of Preparation 1 used in Step A by the compound of Preparation 9, and on the other hand
 the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-
 butyl(dimethyl)silyl]oxy}phenyl)-3-fluoro-4-methylaniline.

Elemental microanalysis:

	%C	%H	%N	%Cl
25 <i>Calculated</i>	67.64	5.69	7.17	4.54
<i>Found</i>	67.08	5.18	7.04	4.28

Example 52: 3-{5-Chloro-2-[(3*S*)-3-[(dimethylamino)methyl]-3,4-dihydro-2(1*H*)-isoquinolinyl]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compounds of Preparations 1 and 1' used in Step A by the respective compounds of Preparations 3 and 8', and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

High-resolution mass (ESI+):

Empirical formula: C₄₃H₄₂³⁵ClN₅O₃

[M+H]⁺ calculated: 712.3054

[M+H]⁺ measured: 712.3060

Rotatory power: (α)_D²⁰ = + 35.8° (c = 6 mg/mL, MeOH)

Example 53: 3-{5-Chloro-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-[4-methoxy-3-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-4-methoxy-3-(trifluoromethyl)aniline.

Elemental microanalysis:

	%C	%H	%N	%Cl
<i>Calculated</i>	63.23	5.19	6.70	4.24
<i>Found</i>	63.08	4.68	6.79	3.92

Example 54: 3-{5-Chloro-2-(((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny)carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-[4-(methylsulphanyl)-3-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

5 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-4-(methylsulphanyl)-3-(trifluoromethyl)aniline.

Elemental microanalysis:

		%C	%H	%N	%S	%Cl
10	<i>Calculated</i>	62.04	5.09	6.58	3.76	4.16
	<i>Found</i>	62.10	4.90	6.61	3.37	3.99

Example 55: 3-{5-Chloro-2-(((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny)carbonyl]phenyl}-*N*-(3-fluoro-4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

15 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}-3-fluorophenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

		%C	%H	%N	%Cl
20	<i>Calculated</i>	66.83	5.48	8.66	4.38
	<i>Found</i>	66.84	4.92	8.68	3.63

Example 56: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-{2-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]phenyl}-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 12, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
10 <i>Calculated</i>	71.84	5.63	9.31	4.71
<i>Found</i>	71.74	5.25	9.24	4.38

Example 57: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-{6-[[((3*S*)-3-[(4-methyl-1-piperazinyl)methyl]-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl}-1-indolizine carboxamide bis(hydrochloride)

The procedure is as in the process of Example 1, replacing on the one hand the compounds of Preparations 1 and 1' used in Step A by the respective compounds of Preparations 13 and 3', and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
20 <i>Calculated</i>	66.74	5.48	9.94	8.38
<i>Found</i>	66.69	5.25	9.80	8.03

Rotatory power: $(\alpha)_D^{20} = +113.2^\circ$ (*c* = 6 mg/mL, MeOH)

Example 58: *N*-(4-Hydroxyphenyl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl]-*N*-phenyl-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 13.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	69.49	5.29	7.54	4.77
Found	69.41	5.00	7.61	4.45

Rotatory power: $(\alpha)_D^{20} = +111.4^\circ$ ($c = 6$ mg/mL, MeOH)

Example 59: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl]-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 13, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	69.38	5.32	8.79	4.45
Found	68.95	5.12	8.57	3.92

Rotatory power: $(\alpha)_D^{20} = +116.8^\circ$ ($c = 5$ mg/mL, MeOH)

Example 60: *N*-(1-Ethyl-1*H*-indol-5-yl)-*N*-(4-hydroxyphenyl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny)carbonyl]-1,3-benzodioxol-5-yl]-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 13, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-ethyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
10 <i>Calculated</i>	69.66	5.47	8.64	4.38
<i>Found</i>	69.81	5.13	8.64	4.30

Example 61: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-2,3-dihydro-1*H*-indol-5-yl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny)carbonyl]-1,3-benzodioxol-5-yl]-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 13, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-5-indolinamine.

High-resolution mass (ESI+):

Empirical formula: C₄₆H₄₃N₅O₆
[M+H]⁺ calculated: 762.3292
[M+H]⁺ measured: 762.3284

Example 62: *N*-(4-Hydroxyphenyl)-*N*-(1-isopropyl-1*H*-indol-5-yl)-3-{6-[[*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 13, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-isopropyl-1*H*-indol-5-amine.

Elemental microanalysis: (theory for 1.3 HCl)

	%C	%H	%N	%Cl
10 <i>Calculated</i>	69.94	5.62	8.50	4.30
<i>Found</i>	69.66	5.50	8.42	4.28

Example 63: *N*-(1-Ethyl-2,3-dihydro-1*H*-indol-5-yl)-*N*-(4-hydroxyphenyl)-3-{6-[[*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 13, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-ethyl-5-indolinamine.

Elemental microanalysis: (theory for 1.3 HCl)

	%C	%H	%N	%Cl
20 <i>Calculated</i>	68.57	5.67	8.51	5.60
<i>Found</i>	68.11	5.23	8.36	5.65

Example 64: *N*-(4-Hydroxyphenyl)-*N*-(1-isopropyl-2,3-dihydro-1*H*-indol-5-yl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 13, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-isopropyl-5-indolinamine.

Elemental microanalysis: (theory for 1.3 HCl)

	%C	%H	%N	%Cl
10 <i>Calculated</i>	68.85	5.81	8.36	5.50
<i>Found</i>	68.58	5.68	8.49	5.10

Example 65: 3-{5-Chloro-2-[[((3*S*)-3-[(4-methyl-1-piperazinyl)methyl]-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl]-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-1-indolizine carboxamide bis(hydrochloride)

The procedure is as in the process of Example 1, replacing on the one hand the compounds of Preparations 1 and 1' used in Step A by the respective compounds of Preparations 14 and 3', and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis: (theory for 1.9 HCl)

	%C	%H	%N	%Cl
20 <i>Calculated</i>	66.36	5.44	10.09	8.09
<i>Found</i>	66.35	5.38	9.86	7.70

Example 66: 3-{5-Chloro-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-2,3-dihydro-1*H*-indol-5-yl)-1-indolizine carboxamide bis(hydrochloride)

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 14, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-5-indolinamine.

Elemental microanalysis:

	%C	%H	%N	%Cl
10 <i>Calculated</i>	65.50	5.37	8.49	12.89
<i>Found</i>	66.02	4.91	8.50	12.11

Rotatory power: (α)_D²⁰ = + 142.2° (c = 3.5 mg/mL, MeOH)

Example 67: 3-{5-Chloro-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 14, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
20 <i>Calculated</i>	68.70	5.25	8.90	4.51
<i>Found</i>	68.43	4.88	8.83	4.13

Rotatory power: (α)_D²⁰ = + 133.3° (c = 3.5 mg/mL, MeOH)

Example 68: 3-{5-Chloro-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl]carbonyl}phenyl)-*N*-(4-fluorophenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 14, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-fluorophenyl)-1-methyl-1*H*-indol-5-amine, it being understood that step D is then limited to a step of formation of the hydrochloride.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	68.53	5.11	8.88	4.49
Found	68.48	4.71	9.09	4.28

Example 69: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1,2,3,4-tetrahydro-6-quinolinyl)-3-{7-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl]carbonyl}-2,3-dihydro-1,4-benzodioxin-6-yl)-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 15, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-1-methyl-1,2,3,4-tetrahydro-6-quinolinamine.

High-resolution mass (ESI+):

Empirical formula: C₄₈H₄₇N₅O₆

[M+H]⁺ calculated: 790.3605

[M+H]⁺ measured: 790.3591

Example 70: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-{7-[(*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-2,3-dihydro-1,4-benzodioxin-6-yl}-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 15, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

		%C	%H	%N	%Cl	%Cl ⁻
10	Calculated	69.66	5.47	8.64	4.38	4.38
	Found	69.45	4.68	8.56	4.64	4.21

Example 71: *N*-(4-Hydroxyphenyl)-3-{5-methoxy-2-[(*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]phenyl}-*N*-(1-methyl-1*H*-indol-5-yl)-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 16, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

High-resolution mass (ESI+):

Empirical formula: C₄₆H₄₃N₅O₅

[M+H]⁺ calculated: 746.3342

[M+H]⁺ measured: 746.3348

Example 72: *Tert*-butyl 8-[[4-hydroxy(1-methyl-1*H*-indol-5-yl)anilino]carbonyl]-6-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl]-3,4-dihydropyrrolo[1,2-*a*]pyrazine-2(1*H*)-carboxylate

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 17, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine, it being understood that the product so obtained is not subjected to a step of salt formation in the presence of ethereal hydrogen chloride.

Elemental microanalysis:

	%C	%H	%N
<i>Calculated</i>	69.43	6.06	9.72
<i>Found</i>	69.41	5.84	9.68

Example 73: *Tert*-butyl 8-[[4-hydroxy(1-methyl-2,3-dihydro-1*H*-indol-5-yl)anilino]carbonyl]-6-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl]-3,4-dihydropyrrolo[1,2-*a*]pyrazine-2(1*H*)-carboxylate

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 17, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-5-indolinamine, it being understood that the product so obtained is not subjected to a step of salt formation in the presence of ethereal hydrogen chloride.

Elemental microanalysis:

	%C	%H	%N
<i>Calculated</i>	69.27	6.28	9.69
<i>Found</i>	69.20	6.11	9.77

Example 74: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-6-{6-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl]carbonyl]-1,3-benzodioxol-5-yl]-1,2,3,4-tetrahydropyrrolo[1,2-*a*]pyrazine-8-carboxamide bis(hydrochloride)

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 17, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine, it being understood that the product so obtained is not subjected to a step of salt formation in the presence of ethereal hydrogen chloride as described in Example 1, Step D. The compound so obtained is deprotected in the presence of 10 equivalents of trifluoroacetic acid in dichloromethane (10 mL/mmol) at ambient temperature overnight. Then, the product is subsequently isolated by concentrating the reaction mixture to dryness. It is finally subjected to a step of salt formation in the presence of ethereal hydrogen chloride.

Elemental microanalysis: (theory for 1.9 HCl)

	%C	%H	%N	%Cl
<i>Calculated</i>	64.80	5.55	10.08	8.08
<i>Found</i>	64.48	5.41	9.85	7.84

Example 75: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-2,3-dihydro-1*H*-indol-5-yl)-6-{6-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl]carbonyl]-1,3-benzodioxol-5-yl]-1,2,3,4-tetrahydropyrrolo[1,2-*a*]pyrazine-8-carboxamide tris(hydrochloride)

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 17, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-5-indolinamine, it being understood that the product so obtained is not subjected to a step of salt formation in the presence of ethereal hydrogen chloride as described in Example 1, Step D. The compound so obtained is deprotected in the presence of 10 equivalents of trifluoroacetic acid in dichloromethane

(10 mL/mmol) at ambient temperature overnight. Then, the product is subsequently isolated by concentrating the reaction mixture to dryness. It is finally subjected to a step of salt formation in the presence of ethereal hydrogen chloride.

5 **Elemental microanalysis:**

	%C	%H	%N	%Cl
<i>Calculated</i>	61.68	5.64	9.59	12.14
<i>Found</i>	61.65	5.35	9.45	11.72

10 **Example 76:** *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5-{6-[[((3*S*)-3-[(4-methyl-1-piperazinyl)methyl]-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl]-2,3-dihydro-1*H*-pyrrolizine-7-carboxamide bis(hydrochloride)

The procedure is as in the process of Example 1, replacing on the one hand the compounds of Preparations 1 and 1' used in Step A by the respective compounds of Preparations 18 and 3', and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-
15 {[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

High-resolution mass (ESI+):

Empirical formula: C₄₆H₄₆N₆O₅

[M+H]⁺ calculated: 763.3608

[M+H]⁺ measured: 763.3594

20 **Example 77:** 5-{5-Chloro-2-[[((3*S*)-3-[(4-methyl-1-piperazinyl)methyl]-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]phenyl]-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-2,3-dihydro-1*H*-pyrrolizine-7-carboxamide bis(hydrochloride)

The procedure is as in the process of Example 1, replacing on the one hand the compounds of Preparations 1 and 1' used in Step A by the respective compounds of Preparations 19 and 3', and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-
25 {[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis: (theory for 1.9 HCl)

	%C	%H	%N	%Cl
<i>Calculated</i>	65.70	5.75	10.22	8.19
<i>Found</i>	65.46	5.55	10.68	7.65

5 **Example 78:** 6-{5-Chloro-2-(((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-phenyl-3,4-dihydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine-8-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1 used in Step A by the compound of Preparation 20.

10 **Elemental microanalysis:**

	%C	%H	%N	%Cl
<i>Calculated</i>	66.57	5.45	7.57	4.79
<i>Found</i>	66.22	5.23	7.53	4.57

15 **Example 79:** 6-{5-Chloro-2-(((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]phenyl}-*N*-(2,3-dihydro-1*H*-indol-5-yl)-*N*-(4-hydroxyphenyl)-3,4-dihydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine-8-carboxamide bis(hydrochloride)

20 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 20, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-([*tert*-butyl(dimethyl)silyl]oxy)phenyl)-5-indolinamine.

Elemental microanalysis:

	%C	%H	%N	%Cl
<i>Calculated</i>	63.20	5.43	8.57	8.68
<i>Found</i>	62.64	5.19	8.39	8.03

Example 80: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-6-{6-[(*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl}-3,4-dihydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine-8-carboxamide

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 21, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine, it being understood that the product so obtained is not subjected to a step of salt formation in the presence of ethereal hydrogen chloride.

Elemental microanalysis:

	%C	%H	%N
<i>Calculated</i>	70.57	5.66	9.14
<i>Found</i>	69.99	5.53	9.04

Example 81: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-2,3-dihydro-1*H*-indol-5-yl)-6-{6-[(*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl}-3,4-dihydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine-8-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 21, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-5-indolinamine.

Elemental microanalysis:

	%C	%H	%N	%Cl
<i>Calculated</i>	67.20	5.76	8.71	4.41
<i>Found</i>	66.67	5.60	8.66	5.10

Example 82: 6-{5-Chloro-2-[(*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(*1H*)-isoquinoliny]carbonyl]phenyl}-*N*-(3-fluoro-4-methylphenyl)-*N*-(4-hydroxyphenyl)-3,4-dihydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine-8-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 20, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-3-fluoro-4-methylaniline.

Elemental microanalysis:

	%C	%H	%N	%Cl	%Cl ⁻
10 Calculated	65.37	5.35	7.26	9.19	4.59
Found	65.49	4.67	7.45	9.18	4.40

Rotatory power: (α)_D²⁰ = + 35.0° (c = 6 mg/mL, MeOH)

Example 83: 3-{5-Chloro-2-[(*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(*1H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-6-yl)-6,7,8,9-tetrahydro-5*H*-pyrrolo[1,2-*a*]azepine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 22, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

High-resolution mass (ESI+):

Empirical formula: C₄₆H₄₆³⁵ClN₅O₄

[M+H]⁺ calculated: 768.3317

[M+H]⁺ measured: 768.3254

Example 84: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-6-yl)-3-{6-[(*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl}-6,7,8,9-tetrahydro-5*H*-pyrrolo[1,2-*a*]azepine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 23, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	69.32	5.94	8.60	4.35
Found	69.42	5.52	8.74	4.05

Rotatory power: (α)_D²⁰ = + 86.6° (c = 8 mg/mL, MeOH)

Example 85: 3-{5-Chloro-2-[(*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(3-thienyl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-3-thiophenamine.

Elemental microanalysis:

	%C	%H	%N	%S	%Cl
Calculated	64.60	5.42	7.53	4.31	4.77
Found	64.67	5.05	7.37	3.90	4.19

Example 86: 6-{5-Chloro-2-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl}phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3,4-dihydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine-8-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 20, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

High-resolution mass (ESI+):

Empirical formula: C₄₄H₄₂³⁵ClN₅O₅

[M+H]⁺ calculated: 756.2953

[M+H]⁺ measured: 756.2936

Example 87: *N*-Butyl-*N*-(4-hydroxyphenyl)-3-{6-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1" used in Step C by *N*-butyl-4-{[*tert*-butyl(dimethyl)silyl]oxy}aniline.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	67.71	6.51	7.70	4.87
Found	67.48	6.30	7.74	5.01

Example 88: *N*-Butyl-*N*-[(3-{6-[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indoliziny]-methyl]-1-butanamine hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1" used in Step C by la *N,N*-dibutylamine, it being understood that Step D is then limited to a step of formation of the hydrochloride.

High-resolution mass (ESI+):

Empirical formula: C₃₉H₅₀N₄O₅

[M+H]⁺ calculated: 655.3859

[M+H]⁺ measured: 655.3826

5 **Example 89:** 3-{5-Chloro-2-(((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]phenyl}-*N*-(3-hydroxypropyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

10 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(3-[[*tert*-butyl(dimethyl)silyl]oxy]propyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl	%Cl ⁻
15 <i>Calculated</i>	66.66	6.26	9.25	9.37	4.68
<i>Found</i>	66.51	5.87	9.25	9.12	4.21

Example 90: 3-{5-Chloro-2-(((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinolinyl)carbonyl]phenyl}-*N*-(4-hydroxybutyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride

20 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(3-[[*tert*-butyl(dimethyl)silyl]oxy]butyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
<i>Calculated</i>	67.01	6.41	9.09	4.60
<i>Found</i>	66.93	5.88	9.23	4.30

5 **Example 91:** *N*-(3-Fluoro-4-methylphenyl)-3-(5-fluoro-2-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}phenyl)-*N*-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 4, and on the other hand
10 the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-3-fluoro-4-methylaniline.

Elemental microanalysis:

	%C	%H	%N	%Cl
<i>Calculated</i>	68.56	5.75	7.44	4.71
15 <i>Found</i>	68.57	5.23	7.53	4.74

Example 92: *N*-(3-Fluoro-4-methylphenyl)-*N*-(4-hydroxyphenyl)-6-(6-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)-3,4-dihydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine-8-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound
20 of Preparation 1 used in Step A by the compound of Preparation 21, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-3-fluoro-4-methylaniline.

Elemental microanalysis:

	%C	%H	%N	%Cl
25 <i>Calculated</i>	66.11	5.42	7.17	4.54
<i>Found</i>	66.02	4.92	7.13	4.26

Example 93: 3-(5-Chloro-2-[[*(3R)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(*1H*)-yl]carbonyl]phenyl)-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compounds of Preparations 1 and 1' used in Step A by the compounds of Preparations 3 and 2', and on the other hand the compound of Preparation 1'' used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl	%Cl'
10 Calculated	68.35	5.74	8.86	8.97	4.48
Found	68.27	5.14	8.92	8.70	4.08

Example 94: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indazol-5-yl)-3-(6-[[*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(*1H*)-yl]carbonyl]-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1'' used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-1-methyl-1*H*-indazol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
20 Calculated	67.45	5.66	10.49	4.42
Found	67.40	5.19	10.40	4.11

Example 95: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-(5-methyl-2-[[*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl]phenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 25, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	71.72	6.28	9.09	4.60
Found	71.17	5.66	8.85	4.47

Example 96: *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5-(6-[[*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl]-1,3-benzodioxol-5-yl)-2,3-dihydro-1*H*-pyrrolizine-7-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 18, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	68.74	5.64	8.91	4.51
Found	68.41	4.96	8.84	4.31

Example 97: *N*-(3-Chloro-4-methylphenyl)-3-(5-chloro-2-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}phenyl)-*N*-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-3-chloro-4-methylaniline.

Elemental microanalysis:

	%C	%H	%N	%Cl
10 <i>Calculated</i>	65.69	5.51	7.13	4.51
<i>Found</i>	65.58	5.03	7.05	4.25

Example 98: *N*-(3-Fluoro-4-methylphenyl)-6-(5-fluoro-2-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}phenyl)-*N*-(4-hydroxyphenyl)-3,4-dihydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine-8-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 26, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-3-fluoro-4-methylaniline.

High-resolution mass (ESI+):

Empirical formula: C₄₂H₄₀F₂N₄O₅
 [M+H]⁺ calculated: 719.3045
 [M+H]⁺ measured: 719.3030

Example 99: 6-(5-Fluoro-2-[[[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]phenyl)-N-(4-fluorophenyl)-N-(4-hydroxyphenyl)-3,4-dihydro-1H-pyrrolo[2,1-c][1,4]oxazine-8-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 26, and on the other hand the compound of Preparation 1" used in Step C by 4-{[*tert*-butyl(dimethyl)silyl]oxy}-N-(4-fluorophenyl)aniline.

High-resolution mass (ESI+):

Empirical formula: C₄₁H₃₈F₂N₄O₅

[M+H]⁺ calculated: 705.2889

[M+H]⁺ measured: 705.2882

Example 100: 3-(5-Fluoro-2-[[[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]phenyl)-7-hydroxy-N-(4-hydroxyphenyl)-N-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

Step A: Methyl 3'-(5-fluoro-2-[[[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]phenyl)-5',6'-dihydro-8'H-spiro[1,3-dioxolane-2,7'-indolizine]-1'-carboxylate

The procedure is as in the process of Step A of Example 1, replacing the compound of Preparation 1 by the compound of Preparation 27.

Step B: Methyl 3-(5-fluoro-2-[[[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]phenyl)-7-(prop-2-en-1-yloxy)-5,6,7,8-tetrahydroindolizine-1-carboxylate

The procedure is as in the process of Steps B, C and D of Example 113.

Step C: N-(4-{[*tert*-Butyl(dimethyl)silyl]oxy}phenyl)-3-(5-fluoro-2-[[[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]phenyl)-N-phenyl-7-(prop-2-en-1-yloxy)-5,6,7,8-tetrahydroindolizine-1-carboxamide

The procedure is as in the processes of Steps B and C of Example 1.

Step D: *N*-(4-[[*tert*-Butyl(dimethyl)silyl]oxy]phenyl)-3-(5-fluoro-2-[[*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl]phenyl)-*N*-phenyl-7-hydroxy-5,6,7,8-tetrahydroindolizine-1-carboxamide

5 There is subsequently carried out a reaction of deprotection of the allyl group in the presence of 1,3-dimethylpyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione (also called dimethyl barbiturate) and of tetrakis(triphenylphosphine)palladium in a mixture of methanol and dichloromethane.

Step E: 3-(5-Fluoro-2-[[*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl]phenyl)-7-hydroxy-*N*-(4-hydroxyphenyl)-*N*-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

10

Deprotection of the *tert*-butylsilyloxy group is carried out according to the process of Step D of Example 1.

Elemental microanalysis:

15

	%C	%H	%N
<i>Calculated</i>	71.98	5.90	7.99
<i>Found</i>	71.18	5.98	7.18

High-resolution mass (ESI+):

Empirical formula: C₄₂H₄₂FN₄O₅

20

[M+H]⁺ calculated: 701.3139

[M+H]⁺ measured: 701.3134

Example 101: 6-(5-Chloro-2-[[*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl]phenyl)-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indazol-5-yl)-3,4-dihydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine-8-carboxamide hydrochloride

25

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 20, and on the other hand

the compound of Preparation 1" used in Step C by *N*-(4-([*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indazol-5-amine.

Elemental microanalysis:

	%C	%H	%N
5 <i>Calculated</i>	65.07	5.33	10.59
<i>Found</i>	65.54	4.86	10.57

Example 102: (2*R*)-5-(5-Fluoro-2-([(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydro-isoquinolin-2(1*H*)-yl]carbonyl}phenyl)-2-hydroxy-*N*-(4-hydroxyphenyl)-*N*-phenyl-2,3-dihydro-1*H*-pyrrolizine-7-carboxamide hydrochloride

10 **Step A:** *Methyl* (2*R*)-2-([*tert*-butyl(dimethyl)silyl]oxy}-5-(5-fluoro-2-([(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}phenyl)-2,3-dihydro-1*H*-pyrrolizine-7-carboxylate

The procedure is as in the process of Step A of Example 1, replacing the compound of Preparation 1 by the compound of Preparation 28.

15 **Step B:** *Methyl* (2*R*)-5-(5-fluoro-2-([(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydro-isoquinolin-2(1*H*)-yl]carbonyl}phenyl)-2-hydroxy-2,3-dihydro-1*H*-pyrrolizine-7-carboxylate

To a solution of the compound of Step A (1 g; 1.54 mmol) in THF (8 mL) there is added a 1 M tetrabutylammonium fluoride solution (1.7 mL; 1.7 mmol). The reaction mixture is stirred for 3 hours at ambient temperature, and then the THF is evaporated off and replaced by ethyl acetate. The organic phase is washed with water and then with brine, before being dried over MgSO₄, filtered and concentrated to dryness. The crude product obtained (830 mg) is used as such in the following step.

25 **¹H-NMR:** δ (500 MHz; dms_o-d₆; 300°K) 7.55-6.9 (m, 7H, H aromatic); 6.55-6.35 (m, 1H, H aromatic dihydropyrrolizine); 5.5-5.3 (m, 1H, alcohol); 5.25-4.6 (m, 1H, H tertiary tetrahydroisoquinoline); 5.0-4.2 (m, 2H, H aliphatic tetrahydroisoquinoline); 4.95-4.62 (m, 1H, HCOH); 3.7-3.6 (sl, 3H, OMe); 3.6-3.2. (m, 2H, 2H, H aliphatic dihydropyrrolizine);

3.7-3.5 (m, 4H, H morpholine); 3.0-2.4 (m, 2H, H aliphatic tetrahydroisoquinoline); 2.6-1.96 (m, 4H, H morpholine); 2.6-1.96 (m, 2H, H aliphatic dihydropyrrolizine)

Step C: *Methyl (2R)-5-(5-fluoro-2-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]phenyl)-2-(prop-2-en-1-yloxy)-2,3-dihydro-1H-pyrrolizine-7-carboxylate*

To a suspension of 62 mg (1.54 mmol) of sodium hydride in 8 mL of anhydrous THF cooled to 0°C there is added a solution of the compound of Step B (820 mg; 1.54 mmol) in THF (6 mL). The suspension is stirred for 15 minutes at 0°C. There is subsequently added 0.15 mL (1.69 mmol) of allyl bromide, dropwise. The reaction mixture is stirred for 5 hours at ambient temperature, and then hydrolysed with a saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The organic phase is dried over MgSO₄, filtered and concentrated to dryness. The oil so obtained is purified by flash chromatography (gradient: dichloromethane/ammoniacal methanol) to yield the title product in solid form.

¹H-NMR: δ (500 MHz; dmso-d₆; 300°K): 7.5-6.8 (m, 7H, H aromatic); 6.55-6.3 (m, 1H, H aromatic dihydropyrrolizine); 5.9 (s, 1H, H allyl); 5.3-5.2 (m, 2H, H allyl); 5.2-5.0 (m, 1H, H tertiary tetrahydroisoquinoline); 5.0-4.2 (m, 2H, H aliphatic tetrahydroindolizine); 4.7-4.42 (m, 1H, HCOallyl); 4.6-3.85 (m, 2H, H aliphatic dihydropyrrolizine); 4.6-3.85 (m, 2H, CH₂ allylic); 3.7-3.5 (m, 3H, OMe); 3.65-3.5 (m, 4H, morpholine); 3.3-2.4 (m, 4H, morpholine and H aliphatic dihydropyrrolidine); 2.4-1.7 (m, 6H, morpholine and CH₂N)

Step D: *(2R)-N-(4-[[tert-Butyl(dimethyl)silyl]oxy]phenyl)-5-(5-fluoro-2-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]phenyl)-N-phenyl-2-(prop-2-en-1-yloxy)-2,3-dihydro-1H-pyrrolizine-7-carboxamide*

The procedure is as in the processes of Steps B and C of Example 1.

Step E: *(2R)-N-(4-[[tert-Butyl(dimethyl)silyl]oxy]phenyl)-5-(5-fluoro-2-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]phenyl)-2-hydroxy-N-phenyl-2,3-dihydro-1H-pyrrolizine-7-carboxamide*

There is then carried out a reaction of deprotection of the allyl group in the presence of 1,3-

dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (also called dimethyl barbiturate) and of tetrakis(triphenylphosphine)palladium (*Synlett*, **2007**, 21, p. 3136).

Step F: (2*R*)-5-(5-Fluoro-2-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydro-isoquinolin-2(1*H*)-yl]carbonyl}phenyl)-2-hydroxy-*N*-(4-hydroxyphenyl)-*N*-phenyl-2,3-dihydro-1*H*-pyrrolizine-7-carboxamide hydrochloride

Deprotection of the *tert*-butylsilyloxy group is carried out according to the process of Step D of Example 1.

Elemental microanalysis:

		%C	%H	%N	%Cl
10	<i>Calculated</i>	68.09	5.57	7.75	4.90
	<i>Found</i>	67.73	5.10	7.54	4.84

High-resolution mass (ESI+):

Empirical formula: C₄₁FH₃₉N₄O₅

[M+H]⁺ calculated: 687.2983

15 [M+H]⁺ measured: 687.2958

Example 103: 3-(5-Chloro-2-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}phenyl)-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-pyrrolo[2,3-*b*]-pyridin-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide

20 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{*tert*-butyl(dimethyl)silyl}oxy)phenyl)-1-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-5-amine.

High-resolution mass (ESI+):

Empirical formula: C₄₄ClH₄₄N₆O₄

25 [M+H]⁺ calculated: 755.3113

[M+H]⁺ measured: 755.3088

Example 104: *N*-(4-Hydroxyphenyl)-3-(5-methoxy-2-[[*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(*1H*)-yl]carbonyl]phenyl)-*N*-(1-methyl-1*H*-indazol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 6, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-1-methyl-1*H*-indazol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
10 <i>Calculated</i>	68.65	6.02	10.67	4.50
<i>Found</i>	67.91	5.52	10.53	4.08

Example 105: *N*-(4-Hydroxyphenyl)-3-(6-[[*(3S)*-3-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]-3,4-dihydroisoquinolin-2(*1H*)-yl]carbonyl]-1,3-benzodioxol-5-yl)-*N*-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide bis(hydrochloride)

The procedure is as in the process of Example 1, replacing the compound of Preparation 1' used in Step A by the compound of Preparation 9'.

Elemental microanalysis:

	%C	%H	%N
<i>Calculated</i>	65.71	6.11	8.33
20 <i>Found</i>	66.57	6.16	8.44

Example 106: (2*S*)-5-(5-Fluoro-2-[[*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(*1H*)-yl]carbonyl]phenyl)-2-hydroxy-*N*-(4-hydroxyphenyl)-*N*-phenyl-2,3-dihydro-1*H*-pyrrolizine-7-carboxamide hydrochloride

The procedure is as in the process of Example 102 replacing the compound of

Preparation 28 used in Step A by the compound of Preparation 29.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	68.09	5.57	7.75	4.90
5 Found	68.16	5.13	7.74	4.97

Example 107: 3-(5-Chloro-2-{[(3*S*)-3-[(4-methyl-3-oxopiperazin-1-yl)methyl]-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}phenyl)-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

10 The procedure is as in the process of Example 1, replacing on the one hand the compounds of Preparations 1 and 1' used in Step A by the respective compounds of Preparations 3 and 10', and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl	%Cl
15 Calculated	67.56	5.67	10.28	8.67	4.34
Found	67.31	5.14	10.18	8.27	3.76

Example 108: 3-(5-Chloro-2-{[(3*S*)-3-[(2-methoxyethyl)(methyl)amino]methyl]-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}phenyl)-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

20 The procedure is as in the process of Example 1, replacing on the one hand the compounds of Preparations 1 and 1' used in Step A by the respective compounds of Preparations 3 and 11', and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
<i>Calculated</i>	68.18	5.98	8.83	4.47
<i>Found</i>	68.30	5.61	8.78	4.46

5 **Example 109:** *N*-(4-Hydroxyphenyl)-3-(6-{[(3*S*)-3-[(4-oxidomorpholin-4-yl)methyl]-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)-*N*-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide

To a solution of the compound of Example 1, taken in the form of the free base, in 10 mL of CH₂Cl₂ there is added in portions *meta*-chloroperbenzoic acid (0.242 mg; 1.4 mmol).
 10 The whole is subsequently stirred at ambient temperature overnight. The reaction mixture is subsequently concentrated to dryness, and then the residue is purified by reverse-phase flash chromatography (gradient: acetonitrile/water/trifluoroacetic acid). There is obtained, after concentration, the title product in the form of a solid.

Elemental microanalysis:

15

	%C	%H	%N
<i>Calculated</i>	71.06	5.82	7.71
<i>Found</i>	70.59	5.36	7.69

High-resolution mass (ESI+):

Empirical formula: C₄₃H₄₂N₄O₇
 20 [M+H]⁺ calculated: 727.3132
 [M+H]⁺ measured: 727.3110

Example 110: 3-(5-Chloro-2-{[(3*S*)-3-{[ethyl(2-methoxyethyl)amino]methyl}-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}phenyl)-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

25 The procedure is as in the process of Example 1, replacing on the one hand the compounds of Preparations 1 and 1' used in Step A by the respective compounds of Preparations 3 and

12', and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-indol-5-amine.

Elemental microanalysis:

		%C	%H	%N	%Cl
5	<i>Calculated</i>	68.48	6.12	8.68	4.39
	<i>Found</i>	68.40	5.78	8.61	4.23

Example 111: 3-(5-Chloro-2-[[*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl]phenyl)-*N*-(4-fluorophenyl)-*N*-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

10 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by 4-{[*tert*-butyl(dimethyl)silyl]oxy}-*N*-(4-fluorophenyl)aniline.

High-resolution mass (ESI+):

15 Empirical formula: C₄₂H₄₀ClN₄O₄
 [M+H]⁺ calculated: 719.2722
 [M+H]⁺ measured: 719.2806

Example 112: *N*-(4-Hydroxyphenyl)-3-(5-methoxy-2-[[*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl]phenyl)-*N*-phenyl-5,6,7,8-tetrahydro-indolizine-1-carboxamide hydrochloride

20

The procedure is as in the process of Example 1, replacing the compound of Preparation 1 used in Step A by the compound of Preparation 6.

Elemental microanalysis:

	%C	%H	%N	%Cl
<i>Calculated</i>	70.43	6.19	7.64	4.83
<i>Found</i>	70.17	5.79	7.60	4.69

5 **Example 113: 7-Hydroxy-N-(4-hydroxyphenyl)-3-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride**

10 **Step A:** Methyl 3'-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5',6'-dihydro-8'H-spiro[1,3-dioxolane-2,7'-indolizine]-1'-carboxylate

The procedure is as in the process of Step A of Example 1, replacing the compound of Preparation 1 by the compound of Preparation 30.

15 **Step B:** Methyl 3-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-7-oxo-5,6,7,8-tetrahydroindolizine-1-carboxylate

20 2.75 g of the compound of Step A (4.47 mmol) in solution in 75 mL of THF are stirred in the presence of 37 mL of 1 M HCl at reflux for 15 hours. 100 mL of water and 100 mL of ethyl acetate are added to the reaction mixture. There are subsequently added 4 g of NaHCO₃ (4.7 mmol) in powder form until a basic pH is reached. The compound is extracted with ethyl acetate, and the organic phase is dried over MgSO₄, filtered and concentrated to dryness. The title product is obtained in the form of an oil.

25 **¹H-NMR:** δ (500MHz; dmso-d₆; 300°K): 7.9-7.2 (m, 4H, H aromatic); 7.02 (m, 1H, H aromatic); 6.88 (m, 1H, H aromatic); 6.44-5.87 (m, 1H, H aromatic tetrahydroindolizine); 6.17 (d, 2H, CH₂ methylenedioxy); 5.07/4.85/3.79 (m, 1H, H tertiary tetrahydroisoquinoline); 4.88/4.27/4.24 (m, 2H, H aliphatic tetrahydroisoquinoline); 4.22-3.43 (m, 4H, H aliphatic tetrahydroindolizine); 3.59-3.49 (m, 4H, H aliphatic morpholine); 3.75-3.52 (s, 3H, Me); 2.93-2.49 (m, 2H, H aliphatic tetrahydroindolizine); 2.75-2.28 (m, 2H, H aliphatic tetrahydroindolizine); 2.68-1.68 (m, 6H, H aliphatic morpholine + CH₂)

Step C: *Methyl* *7-hydroxy-3-(6-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxylate*

To a solution of 2.55 g of the compound obtained in Step B (4.47 mmol) in 30 mL of methanol there are added in portions 558 mg (14.75 mmol) of sodium borohydride. The reaction mixture is stirred for one hour at ambient temperature. 50 mL of 1M HCl are subsequently added, and the methanol is evaporated off. The aqueous phase is subsequently neutralised with NaHCO₃ and then extracted with dichloromethane. The organic phase is washed in succession with H₂O, dried over MgSO₄, filtered and concentrated to dryness. The oil so obtained is purified by flash chromatography (dichloromethane/ethanol-ammonia gradient). The title product is obtained in the form of a solid.

¹H-NMR: δ (500MHz; dmso-d₆; 300°K): 7.22-6.97 (m, 4H, H aromatic tetrahydroisoquinoline); 7.05 (s, 1H, H aromatic); 6.89 (s, 1H, H aromatic); 6.37/6.3/6.07 (m, 1H, H aromatic tetrahydroindolizine); 6.16 (d, 2H, CH₂ methylenedioxy); 5.09 (m, 1H, H tertiary tetrahydroisoquinoline); 4.87-4.21 (m, 2H, H aliphatic tetrahydroindolizine); 4.20-3.67 (m, 2H, H aliphatic tetrahydroindolizine); 4.10-3.86 (m, 1H, H tertiary tetrahydroindolizine); 3.69-3.58 (s, 3H, Me); 3.69-3.52 (m, 4H, H aliphatic morpholine); 2.96 + 2.43 (m, 2H, H aliphatic tetrahydroisoquinoline); 2.55-2.0 (m, 6H, H aliphatic morpholine + CH₂); 2.4-1.5 (m, 4H, H aliphatic tetrahydroindolizine)

IR: OH: 3239 cm⁻¹; -C=O (ester): 1696 cm⁻¹; -C=O (amide): 1624 cm⁻¹; C-C-OH (secondary alcohol): 1034 cm⁻¹

Step D: *Methyl* *3-(6-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]-1,3-benzodioxol-5-yl)-7-(prop-2-en-1-yloxy)-5,6,7,8-tetrahydroindolizine-1-carboxylate*

To a suspension of 331 mg (8.26 mmol) of sodium hydride in 15 mL of anhydrous THF cooled to 0°C there are added 2.37 g (4.13 mmol) of the compound obtained in Step C. The suspension is stirred for 15 minutes at 0°C, and then a solution of 790 µL (9.1 mmol) of allyl bromide in 10 mL of THF is added slowly (over a period of 15 minutes). The

reaction mixture is stirred for one hour at 0°C and then for 15 hours at ambient temperature. The solution is hydrolysed with a saturated aqueous NH₄Cl solution. The compound is extracted with ethyl acetate; the organic phase is dried over MgSO₄, filtered and concentrated to dryness. The oil so obtained is purified by flash chromatography (cyclohexane/ethyl acetate gradient). The title product is obtained in the form of a solid.

¹H-NMR: δ (500 MHz; dms_o-d₆; 300°K): 7.2-6.9 (m, 4H, H aromatic tetrahydroisoquinoline); 7.2-6.8 (m, 2H, H aromatic); 6.4-6.0 (m, 1H, H aromatic tetrahydroindolizine); 6.10 (d, 2H, CH₂ methylenedioxy); 5.9 (m, 1H, allyl); 5.35-5.10 (m, 2H, allyl); 5.1+4.75 (m, 1H, H tertiary tetrahydroisoquinoline); 4.15-3.9 (m, 2H, CH₂ allyl); 3.9-3.6 (m, 1H, H tertiary tetrahydroindolizine); 4.1-3.4 (m, 4H, H aliphatic morpholine); 4.9-3.4 (m, 4H, 2H aliphatic tetrahydroindolizine + 2H aliphatic tetrahydroisoquinoline); 3.8-3.6 (s, 3H, Me); 2.55-1.6 (m, 6H, H aliphatic morpholine + CH₂); 3.3-1.5 (m, 6H, 4H aliphatic tetrahydroindolizine + 2H aliphatic tetrahydroisoquinoline)

Step E: *N-(4-{{tert-Butyl(dimethyl)silyl}oxy}phenyl)-3-(6-[[[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]-1,3-benzodioxol-5-yl]-N-phenyl-7-(prop-2-en-1-yloxy)-5,6,7,8-tetrahydroindolizine-1-carboxamide*

The procedure is as in the processes of Steps B and C of Example 1.

Step F: *N-(4-{{tert-Butyl(dimethyl)silyl}oxy}phenyl)-7-hydroxy-3-(6-[[[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]-1,3-benzodioxol-5-yl]-N-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide*

There is then carried out a reaction of deprotection of the allyl group in the presence of 1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (also called dimethyl barbiturate) and of tetrakis(triphenylphosphine)palladium in a mixture of methanol and dichloromethane.

Step G: *7-Hydroxy-N-(4-hydroxyphenyl)-3-(6-[[[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]-1,3-benzodioxol-5-yl]-N-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride*

Deprotection of the silyloxy group is carried out according to the process of Step D of

Example 1.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	67.66	5.68	7.34	4.64
5 Found	67.02	5.27	7.36	4.61

High-resolution mass (ESI+):

Empirical formula: C₄₃H₄₃N₄O₇

[M+H]⁺ calculated: 727.3132

[M+H]⁺ measured: 727.3121

10 **Example 114:** *N*-(3-Fluoro-4-methylphenyl)-*N*-(4-hydroxyphenyl)-3-(5-methoxy-2-
 {[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}phenyl)-
 5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

15 The procedure is as in the process of Example 1, replacing on the one hand the compound
 of Preparation 1 used in Step A by the compound of Preparation 6, and on the other hand
 the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-
 butyl(dimethyl)silyl]oxy}phenyl)-3-fluoro-4-methylaniline.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	69.05	6.06	7.32	4.63
20 Found	68.90	5.56	7.33	4.41

Example 115: 3-(5-Chloro-2-[[[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-
 2(1*H*)-yl]carbonyl}phenyl)-*N*-(2-fluorophenyl)-*N*-(4-hydroxyphenyl)-5,6,7,8-
 tetrahydroindolizine-1-carboxamide hydrochloride

25 The procedure is as in the process of Example 1, replacing on the one hand the compound
 of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand

the compound of Preparation 1" used in Step C by 4- $\{[tert\text{-butyl(dimethyl)silyl}]\text{oxy}\}$ -*N*-(2-fluorophenyl)aniline.

High-resolution mass (ESI+):

Empirical formula: C₄₂H₄₀ClN₄O₄

5 [M+H]⁺ calculated: 719.2722

[M+H]⁺ measured: 719.2802

Example 116: 3-(5-Chloro-2- $\{[(3S)\text{-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}\}$ phenyl)-*N*-(3-fluorophenyl)-*N*-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

10 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by 4- $\{[tert\text{-butyl(dimethyl)silyl}]\text{oxy}\}$ -*N*-(3-fluorophenyl)aniline.

High-resolution mass (ESI+):

15 Empirical formula: C₄₂H₄₀ClN₄O₄

[M+H]⁺ calculated: 719.2722

[M+H]⁺ measured: 719.2819

Example 117: 3-(5-Chloro-2- $\{[(3S)\text{-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}\}$ phenyl)-*N*-(2,4-difluorophenyl)-*N*-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

20

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4- $\{[tert\text{-butyl(dimethyl)silyl}]\text{oxy}\}$ phenyl)-2,4-difluoroaniline.

High-resolution mass (ESI+):

Empirical formula: C₄₂H₃₉ClF₂N₄O₄

[M+H]⁺ calculated: 737.2628

[M+H]⁺ measured: 737.2660

5 **Example 118: 3-(5-Chloro-2-[[[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]phenyl)-N-(3,4-difluorophenyl)-N-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride**

10 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by N-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-3,4-difluoroaniline.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	65.20	5.21	7.24	4.58
15 Found	65.26	5.01	6.90	4.57

Example 119: 3-(5-Chloro-2-[[[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]phenyl)-N-(3-cyanophenyl)-N-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

20 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by 3-[(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)amino]benzonitrile.

Elemental microanalysis:

	%C	%H	%N	%Cl
25 Calculated	67.71	5.42	9.18	4.65
Found	67.00	5.20	8.89	4.54

Example 120: *N*-(4-Hydroxyphenyl)-6-(6-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)-*N*-phenylpyrrolo[1,2-*a*]-pyrazine-8-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1 used in Step A by the compound of Preparation 31.

High-resolution mass (ESI+):

Empirical formula: C₄₂H₃₇N₅O₆

[M+H]⁺ calculated: 708.2822

[M+H]⁺ measured: 708.2788

Example 121: *N*-(3-Fluorophenyl)-*N*-(4-hydroxyphenyl)-6-(6-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)pyrrolo[1,2-*a*]pyrazine-8-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 31, and on the other hand the compound of Preparation 1" used in Step C by 4-{[*tert*-butyl(dimethyl)silyl]oxy}-*N*-(3-fluorophenyl)aniline.

High-resolution mass (ESI+):

Empirical formula: C₄₂H₃₆FN₅O₆

[M+H]⁺ calculated: 726.2728

[M+H]⁺ measured: 726.2723

Example 122: *N*-(3-Fluorophenyl)-*N*-(4-hydroxyphenyl)-3-(6-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1"

used in Step C by 4-[[*tert*-butyl(dimethyl)silyl]oxy]-*N*-(3-fluorophenyl)aniline.

High-resolution mass (ESI+):

Empirical formula : C₄₃H₄₁FN₄O₆

[M+H]⁺ calculated : 729.3088

5 [M+H]⁺ measured : 729.3068

Example 123: *N*-(4-Hydroxyphenyl)-3-(6-[[*(3S)*-3-[[4-(methylsulphonyl)piperazin-1-yl]methyl]-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl]-1,3-benzodioxol-5-yl)-*N*-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

10 The procedure is as in the process of Example 1, replacing the compound of Preparation 1' used in Step A by the compound of Preparation 13'.

Elemental microanalysis:

	%C	%H	%N	%S	%Cl
Calculated	64.11	5.62	8.50	3.89	4.30
Found	64.19	5.07	8.52	3.87	4.02

15 **Example 124:** 3-(5-Chloro-2-[[*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl]phenyl)-*N*-(4-hydroxyphenyl)-*N*-(3-methoxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

20 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-3-methoxyaniline.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	67.27	5.78	7.30	4.62
25 Found	67.54	5.35	7.32	4.62

Example 125: 3-(5-Chloro-2-[[[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl]phenyl)-*N*-(3,5-difluorophenyl)-*N*-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-3,5-difluoroaniline.

Elemental microanalysis:

	%C	%H	%N	%Cl
10 <i>Calculated</i>	65.20	5.21	7.24	4.58
<i>Found</i>	65.85	4.93	7.04	4.76

Example 126: 3-(5-Chloro-2-[[[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl]phenyl)-*N*-(4-hydroxyphenyl)-*N*-(3-methylphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-3-methylaniline.

Elemental microanalysis:

	%C	%H	%N	%Cl
20 <i>Calculated</i>	68.70	5.90	7.45	4.72
<i>Found</i>	68.94	5.72	7.21	4.84

Example 127: *N*-(4-Hydroxyphenyl)-*N*-phenyl-3-(6-{[(3*S*)-3-{[4-(2,2,2-trifluoroethyl)-piperazin-1-yl]methyl}-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1' used in Step A by the compound of Preparation 14'.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	65.25	5.48	8.45	4.28
Found	64.91	5.23	8.37	4.96

Example 128: *N*-(4-Hydroxyphenyl)-3-(6-{[(3*S*)-3-{[4-methyl-3-oxopiperazin-1-yl]methyl}-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)-*N*-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1' used in Step A by the compound of Preparation 10'.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	68.25	5.73	9.04	4.58
Found	68.04	5.09	8.82	4.64

Example 129: 3-(5-Chloro-2-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}phenyl)-*N*-(4-cyanophenyl)-*N*-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by 4-[(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)amino]benzonitrile.

Elemental microanalysis:

	%C	%H	%N
Calculated	67.71	5.42	9.18
Found	68.17	5.15	8.71

5 **Example 130:** 3-(5-Chloro-2-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}phenyl)-*N,N*-diphenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand
10 the compound of Preparation 1" used in Step C by *N*-phenylaniline.

High-resolution mass (ESI+):

Empirical formula: C₄₂H₄₀Cl₂N₄O₄

[M+H]⁺ calculated: 735.2427

[M+H]⁺ measured: 735.2524

15 **Example 131:** 3-(5-Chloro-2-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}phenyl)-*N*-(3-chlorophenyl)-*N*-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand
20 the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-3-chloroaniline.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	65.33	5.35	7.26	4.59
25 Found	64.08	5.29	6.92	4.59

Example 132: 3-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N-(pyrimidin-2-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by N-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)pyrimidin-2-amine.

Elemental microanalysis:

	%C	%H	%N
Calculated	64.95	5.45	11.36
Found	64.62	5.07	10.92

Example 133: 3-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(cyclobutylmethyl)-N-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by 4-{[tert-butyl(dimethyl)silyl]oxy}-N-(cyclobutylmethyl)aniline.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	68.16	6.39	7.76	3.93
Found	68.69	5.93	7.45	3.81

Example 134: 3-(5-Chloro-2-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}phenyl)-*N*-(2-cyanophenyl)-*N*-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by 2-[(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)amino]benzonitrile.

Elemental microanalysis:

	%C	%H	%N
10 <i>Calculated</i>	67.71	5.42	9.18
<i>Found</i>	67.34	4.95	8.73

Example 135: 3-(5-Chloro-2-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}phenyl)-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-pyrazol-4-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1*H*-pyrazol-4-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
20 <i>Calculated</i>	64.77	5.71	11.33	4.78
<i>Found</i>	64.62	5.33	10.71	4.10

Example 136: 3-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(cyclopropylmethyl)-N-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by 4-{[*tert*-butyl(dimethyl)silyl]oxy}-N-(cyclopropylmethyl)aniline.

Elemental microanalysis:

	%C	%H	%N	%Cl
10 <i>Calculated</i>	67.13	6.20	7.83	4.95
<i>Found</i>	67.58	5.79	7.36	4.16

Example 137: 3-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N-(1-methyl-1H-pyrazol-3-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by N-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1H-pyrazol-3-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
20 <i>Calculated</i>	64.77	5.71	11.33	4.78
<i>Found</i>	64.20	5.47	10.78	5.27

Example 138: *N*-(But-2-yn-1-yl)-3-(5-chloro-2-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}phenyl)-*N*-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by 4-{[*tert*-butyl(dimethyl)silyl]oxy}-*N*-(but-2-yn-1-yl)aniline.

Elemental microanalysis:

	%C	%H	%N	%Cl
10 <i>Calculated</i>	64.95	5.45	11.36	4.79
<i>Found</i>	65.53	5.19	10.88	5.38

Example 139: 3-(5-Chloro-2-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}phenyl)-*N*-(4-hydroxyphenyl)-*N*-(pyridin-2-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)pyridin-2-amine.

Elemental microanalysis:

	%C	%H	%N
20 <i>Calculated</i>	66.66	5.59	9.48
<i>Found</i>	67.12	5.37	9.11

Example 140: 3-(5-Chloro-2-[[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]phenyl)-N-(4-hydroxyphenyl)-N-(pyridazin-3-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by N-(4-[[tert-butyl(dimethyl)silyl]oxy}phenyl)pyridazin-3-amine.

High-resolution mass (ESI+):

Empirical formula: C₄₂H₃₉ClN₆O₄

[M+H]⁺ calculated: 703.2721

[M+H]⁺ measured: 703.2783

Example 141: 3-(5-Chloro-2-[[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]phenyl)-N-(4-hydroxyphenyl)-N-(pyrimidin-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by N-(4-[[tert-butyl(dimethyl)silyl]oxy}phenyl)pyrimidin-5-amine.

Elemental microanalysis:

	%C	%H	%N	%Cl
Calculated	68.32	5.59	11.95	5.04
Found	68.05	5.52	11.83	5.50

Example 142: 3-(5-Chloro-2-([(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl)phenyl)-N-(4-hydroxyphenyl)-N-(pyridin-3-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide bis(hydrochloride)

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-([*tert*-butyl(dimethyl)silyl]oxy)phenyl)pyridin-3-amine.

High-resolution mass (ESI+):

Empirical formula: C₄₁H₄₀ClN₅O₄

[M+H]⁺ calculated: 702.2769

[M+H]⁺ measured: 702.2858

Example 143: 3-(5-Chloro-2-([(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl)phenyl)-N-(3,5-difluoro-4-methoxyphenyl)-N-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-([*tert*-butyl(dimethyl)silyl]oxy)phenyl)-3,5-difluoro-4-methoxyaniline.

High-resolution mass (ESI+):

Empirical formula: C₄₃H₄₁ClF₂N₄O₅

[M+H]⁺ calculated: 767.2734

[M+H]⁺ measured: 767.2804

Example 144: 3-(5-Chloro-2-([(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N-(pyridin-4-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide bis(hydrochloride)

5 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-([*tert*-butyl(dimethyl)silyl]oxy}phenyl)pyridin-4-amine.

High-resolution mass (ESI+):

Empirical formula: C₄₁H₄₀ClN₅O₄

10 [M+H]⁺ calculated: 702.2842

[M+H]⁺ measured: 702.2842

Example 145: 3-(5-Chloro-2-([(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(3-fluoro-4-methoxyphenyl)-N-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

15 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1" used in Step C by *N*-(4-([*tert*-butyl(dimethyl)silyl]oxy}phenyl)-3-fluoro-4-methoxyaniline.

High-resolution mass (ESI+):

20 Empirical formula: C₄₃H₄₂ClFN₄O₅

[M+H]⁺ calculated: 749.2828

[M+H]⁺ measured: 749.2878

Example 146: *N*-(4-Hydroxyphenyl)-3-(6-{[(3*S*)-3-{[(2-methoxyethyl)(methyl)amino]-methyl}-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)-*N*-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1' used in Step A by the compound of Preparation 11'.

Elemental microanalysis:

	%C	%H	%N	%Cl
<i>Calculated</i>	68.93	6.05	7.48	4.73
<i>Found</i>	68.84	5.85	7.56	4.60

Example 147: 3-(6-{[(3*S*)-3-[(1,1-Dioxidothiomorpholin-4-yl)methyl]-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)-*N*-(4-hydroxyphenyl)-*N*-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1' used in Step A by the compound of Preparation 15'.

Elemental microanalysis:

	%C	%H	%N	%S	%Cl
<i>Calculated</i>	64.94	5.45	7.04	4.03	4.46
<i>Found</i>	65.27	5.13	7.14	3.90	4.30

Example 148: *N*-(5-Hydroxypyrimidin-2-yl)-3-(6-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)-*N*-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide trifluoroacetate

Step A: *N*-[5-(Benzyloxy)pyrimidin-2-yl]-3-(6-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)-*N*-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide

The procedure is as in Steps A, B and C of the process of Example 1, replacing the

compound of Preparation 1" used in Step C by 5-(benzyloxy)-*N*-phenylpyrimidin-2-amine.

Step B: *N*-(5-Hydroxypyrimidin-2-yl)-3-(6-[[[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydro-isoquinolin-2(1*H*)-yl]carbonyl]-1,3-benzodioxol-5-yl)-*N*-phenyl-5,6,7,8-tetrahydro-indolizine-1-carboxamide trifluoroacetate

5 The compound of Step A (150 mg; 0.2 mmol) is dissolved in 8 mL of methanol, and 30 mg of Pd/C (10% by mass palladium) are added. The reaction mixture is stirred under a hydrogen atmosphere (1.2 bar) for 15 hours and is then filtered over a Whatman filter, concentrated *in vacuo* and purified by reverse-phase chromatography (gradient: acetonitrile/water in the presence of trifluoroacetic acid). The desired product is obtained
10 in the form of a trifluoroacetate salt.

High-resolution mass (ESI+):

Empirical formula: C₄₁H₄₀N₆O₆

[M+H]⁺ calculated: 713.3082

[M+H]⁺ measured: 713.3080

15 **Exemple 149 :** *N*-(4-Hydroxyphenyl)-3-(6-[[[(3*S*)-3-[(3-methoxypyrrolidin-1-yl)methyl]-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl]-1,3-benzodioxol-5-yl)-*N*-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1' used in Step A by the compound of Preparation 16'.

20 ***Elemental microanalysis:***

	%C	%H	%N	%Cl
<i>Calculated</i>	69.42	5.96	7.36	4.66
<i>Found</i>	70.19	5.48	7.22	4.53

Exemple 150 : 3-(5-Chloro-2-([(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]phenyl)-N-(3-cyano-4-methoxyphenyl)-N-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1'' used in Step C by 5-[(4-[(*tert*-butyl(dimethyl)silyl]oxy)phenyl)amino]-2-methoxybenzonitrile.

High-resolution mass (ESI+):

Empirical formula: C₄₄H₄₂ClN₅O₅

[M+H]⁺ calculated : 756.2874

[M+H]⁺ measured : 756.2917

Exemple 151 : N-(4-Hydroxyphenyl)-3-(5-methoxy-2-([(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl]phenyl)-N-(1-methyl-1H-pyrazol-4-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 6, and on the other hand the compound of Preparation 1'' used in Step C by N-(4-[(*tert*-butyl(diméthyl)silyl]oxy)phényl)-1-méthyl-1H-pyrazol-4-amine.

High-resolution mass (ESI+):

Empirical formula: C₄₁H₄₄N₆O₅

[M+H]⁺ calculated : 701.3446

[M+H]⁺ measured : 701.3446

Exemple 152 : 3-(5-Chloro-2-[[*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(*1H*)-yl]carbonyl]phenyl)-*N*-(4-hydroxyphenyl)-*N*-[3-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 3, and on the other hand the compound of Preparation 1'' used in Step C by *N*-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-3-(trifluoromethyl)aniline.

High-resolution mass (ESI+):

Empirical formula: C₄₃H₄₀ClF₃N₄O₄

[M+H]⁺ calculated : 769.2690

[M+H]⁺ measured : 769.2718

Exemple 153 : 3-(6-[[*(3S)*-3-[(3,3-Difluoropyrrolidin-1-yl)methyl]-3,4-dihydroisoquinolin-2(*1H*)-yl]carbonyl]-1,3-benzodioxol-5-yl)-*N*-(4-hydroxyphenyl)-*N*-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1' used in Step A by the compound of Preparation 17'.

Elemental microanalysis:

	%C	%H	%N
Calculated	67.31	5.39	7.30
Found	68.07	5.60	7.23

Exemple 154 : *N*-(4-Hydroxyphenyl)-*N*-(1-methyl-1*H*-pyrazol-4-yl)-3-(7-[[*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(*1H*)-yl]carbonyl]-2,3-dihydro-1,4-benzodioxin-6-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 7, and on the other hand

the compound of Preparation 1'' used in Step C by *N*-(4-([*tert*-butyl(diméthyl)silyl]oxy}phényl)-1-méthyl-1*H*-pyrazol-4-amine.

Exemple 155 : *N*-(4-Hydroxyphenyl)-3-(7-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-2,3-dihydro-1,4-benzodioxin-6-yl)-*N*-(pyrimidin-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 7, and on the other hand the compound of Preparation 1'' used in Step C by *N*-(4-([*tert*-butyl(diméthyl)silyl]oxy}phenyl)pyrimidin-5-amine.

Exemple 156 : *N*-(4-Hydroxyphenyl)-3-(6-{[(3*S*)-3-[(3-methoxyazetidin-1-yl)methyl]-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)-*N*-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide

The procedure is as in the process of Example 1, replacing the compound of Preparation 1' used in Step A by the compound of Preparation 18'.

Microanalyse élémentaire :

	%C	%H	%N
<i>Calculated</i>	72.66	5.96	7.88
<i>Found</i>	72.32	5.51	7.96

High-resolution mass (ESI+):

Empirical formula : C₄₃H₄₂N₄O₆

[M+H]⁺ calculated : 711.3177

[M+H]⁺ measured : 711.3178

Exemple 157 : 3-(6-{[(3*S*)-3-[(3-Fluoroazetidin-1-yl)methyl]-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)-*N*-(4-hydroxyphenyl)-*N*-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing the compound of Preparation 1' used in Step A by the compound of Preparation 19'.

Exemple 158 : 3-(5-Fluoro-2-[[*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(*1H*)-yl]carbonyl]phenyl)-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-pyrazol-4-yl)-

5 5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride

The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 4, and on the other hand the compound of Preparation 1'' used in Step C by *N*-(4-[[*tert*-butyl(diméthyl)silyl]oxy]phényl)-1-méthyl-1*H*-pyrazol-4-amine.

10 **Exemple 159 :** 3-(5-Fluoro-2-[[*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(*1H*)-yl]carbonyl]phenyl)-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-pyrazol-4-yl)indolizine-1-carboxamide hydrochloride

15 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 32, and on the other hand the compound of Preparation 1'' used in Step C by *N*-(4-[[*tert*-butyl(diméthyl)silyl]oxy]phényl)-1-méthyl-1*H*-pyrazol-4-amine.

Exemple 160 : 3-(5-Chloro-2-[[*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(*1H*)-yl]carbonyl]phenyl)-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-pyrazol-4-yl)indolizine-1-carboxamide hydrochloride

20 The procedure is as in the process of Example 1, replacing on the one hand the compound of Preparation 1 used in Step A by the compound of Preparation 14, and on the other hand the compound of Preparation 1'' used in Step C by *N*-(4-[[*tert*-butyl(diméthyl)silyl]oxy]phényl)-1-méthyl-1*H*-pyrazol-4-amine.

PHARMACOLOGICAL STUDY

EXAMPLE A: Inhibition of Bcl-2 by the fluorescence polarisation technique

The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50×10^{-8} M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00×10^{-8} M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.

The results are expressed in IC_{50} (the concentration of compound that inhibits fluorescence polarisation by 50%) and are presented in Table 1 below.

The results show that the compounds of the invention inhibit interaction between the Bcl-2 protein and the fluorescent peptide described hereinbefore.

EXAMPLE B: *In vitro* cytotoxicity

The cytotoxicity studies were carried out on the RS4;11 leukaemia tumour line.

The cells are distributed onto microplates and exposed to the test compounds for 48 hours. The cell viability is then quantified by a colorimetric assay, the Microculture Tetrazolium Assay (Cancer Res., 1987, 47, 939-942).

The results are expressed in IC_{50} (the concentration of compound that inhibits cell viability by 50%) and are presented in Table 1 below.

The results show that the compounds of the invention are cytotoxic.

Table 1: IC₅₀ of Bcl-2 inhibition (fluorescence polarisation test)
and of cytotoxicity for RS4;11 cells

	IC ₅₀ (nM) Bcl-2 FP	IC ₅₀ (nM) MTT RS4;11		IC ₅₀ (nM) Bcl-2 FP	IC ₅₀ (nM) MTT RS4;11
Example 1	18	60.1	Example 32	34	71.3
Example 2	20	49.8	Example 33	23	12.2
Example 3	20	44.7	Example 34	27	65.8
Example 4	19	27.1	Example 35	15	11.7
Example 5	51	98	Example 36	43	135
Example 6	15	30	Example 37	19	11.6
Example 8	15	25.6	Example 38	21	61.8
Example 9	13	16.1	Example 39	16	14.1
Example 10	18	11	Example 40	15	32.2
Example 13	12	8.63	Example 41	26	44
Example 14	16	10.7	Example 42	13	53.6
Example 15	17	20.4	Example 43	110	142
Example 16	18	23.4	Example 44	14	45
Example 17	81	120	Example 45	47	76.8
Example 18	32	24.9	Example 46	21	56.8
Example 19	27	42.3	Example 47	58	194
Example 20	35	105	Example 48	130	229
Example 21	22	34.6	Example 49	45	169
Example 22	27	19.1	Example 50	13	4.01
Example 23	14	23	Example 51	32	26
Example 24	17	29.8	Example 52	16	19.8
Example 25	29	143	Example 53	180	138
Example 26	17	40	Example 54	180	106
Example 27	17	35.4	Example 55	34	19.4
Example 28	25	76.1	Example 56	20	25.9
Example 29	35	85.5	Example 57	12	8.62
Example 30	13	8.59	Example 58	22	40.1
Example 31	33	340	Example 59	13	8.13

	IC ₅₀ (nM) Bcl-2 FP	IC ₅₀ (nM) MTT RS4;11		IC ₅₀ (nM) Bcl-2 FP	IC ₅₀ (nM) MTT RS4;11
Example 60	19	11.7	Example 98	12	73.5
Example 61	22	14.5	Example 99	25	213
Example 62	22	19.3	Example 100	22	856
Example 63	21	18.8	Example 101	5	22.1
Example 64	31	23.3	Example 103	6	16.8
Example 65	14	9.19	Example 104	7	21.6
Example 66	16	21.7	Example 105	10	28.9
Example 67	24	17.7	Example 107	7	8.29
Example 69	26	16.7	Example 108	9	36.4
Example 70	19	14	Example 109	30	483
Example 71	21	24.4	Example 110	29	129
Example 72	220	270	Example 111	15	81.5
Example 74	24	241	Example 112	9	139
Example 76	17	49	Example 113	16	190
Example 77	23	70.4	Example 114	9	43.1
Example 78	31	101	Example 115	8	58.1
Example 79	31	67.5	Example 116	10	43.6
Example 80	18	18.8	Example 117	15	194
Example 81	28	39.3	Example 118	15	71
Example 82	33	21.9	Example 119	9	31.6
Example 83	18	41.2	Example 121	34	445
Example 84	18	20.6	Example 122	16	43.5
Example 85	41	246	Example 123	22	92.1
Example 86	22	29.5	Example 124	28	101
Example 87	27	121	Example 125	38	81.8
Example 91	8	65.5	Example 126	26	115
Example 92	5	40.2	Example 127	26	129
Example 94	3	8.16	Example 128	10	63.4
Example 95	6	13.5	Example 129	9	46.7
Example 96	11	58.8	Example 131	30	88.4
Example 97	20	45.4	Example 134	37	305

	IC ₅₀ (nM) Bcl-2 FP	IC ₅₀ (nM) MTT RS4;11		IC ₅₀ (nM) Bcl-2 FP	IC ₅₀ (nM) MTT RS4;11
Example 135	6	37.4	Example 144	n.d.	59.9
Example 141	n.d.	72.5	Example 145	n.d.	28.9
Example 142	n.d.	66.1	Example 146	n.d.	153
Example 143	n.d.	43.8	Example 147	n.d.	74.2

EXAMPLE C: Induction of caspase activity *in vivo*

The ability of the compounds of the invention to activate caspase 3 is evaluated in a xenograft model of RS4;11 leukaemia cells.

1x10⁷ RS4;11 cells are grafted sub-cutaneously into immunosuppressed mice (SCID strain). 25 to 30 days after the graft, the animals are treated orally with the various compounds. Sixteen hours after treatment, the tumour masses are recovered and lysed, and the caspase 3 activity is measured in the tumour lysates.

This enzymatic measurement is carried out by assaying the appearance of a fluorogenic cleavage product (DEVDase activity, Promega). It is expressed in the form of an activation factor corresponding to the ratio between the two caspase activities: the activity for the treated mice divided by the activity for the control mice.

The results obtained are presented in Table 2 and show that the compounds of the invention are capable of inducing apoptosis in RS4;11 tumour cells *in vivo*.

Table 2: Caspase activation factors (DEVDase activity in the tumours of treated mice versus control mice) *in vivo*, after oral treatment (exact doses in brackets)

Compound tested	Activation factor (versus control)
Example 1	29.3 (100 mg/kg)
Example 2	27.8 (100 mg/kg)
Example 3	5.7 (50 mg/kg)
Example 4	29.2 (50 mg/kg)
Example 8	9.8 (50 mg/kg)
Example 9	20.6 (50 mg/kg)
Example 10	13.8 (50 mg/kg)
Example 22	11.3 (50 mg/kg)
Example 23	22.7 (50 mg/kg)
Example 58	23.3 (50 mg/kg)
Example 59	23 (50 mg/kg)
Example 66	24.7 (50 mg/kg)
Example 67	18.9 (50 mg/kg)

EXAMPLE D: Quantification of the cleaved form of caspase 3 *in vivo*

The ability of the compounds of the invention to activate caspase 3 is evaluated in a xenograft model of RS4;11 leukaemia cells.

1×10^7 RS4;11 cells are grafted sub-cutaneously into immunosuppressed mice (SCID strain). 25 to 30 days after the graft, the animals are treated orally with the various compounds. After treatment, the tumour masses are recovered and lysed, and the cleaved (activated) form of caspase 3 is quantified in the tumour lysates.

The quantification is carried out using the "Meso Scale Discovery (MSD) ELISA platform" test, which specifically assays the cleaved form of caspase 3. It is expressed in the form of an activation factor corresponding to the ratio between the quantity of cleaved caspase 3 in the treated mice divided by the quantity of cleaved caspase 3 in the control mice.

The results obtained are presented in Table 3 and show that the compounds of the invention are capable of inducing apoptosis in RS4;11 tumour cells *in vivo*.

Table 3: Caspase activation factors (cleaved caspase 3 MSD test in the tumours of treated mice versus control mice) *in vivo*, after oral treatment (exact doses in brackets)

Compound tested	Activation factor (versus control)
Example 78	10.4 (25 mg/kg)
Example 87	18.3 (50 mg/kg)
Example 122	17.4 (25 mg/kg)
Example 135	60 (50 mg/kg)

EXAMPLE E: Anti-tumour activity *in vivo*

The anti-tumour activity of the compounds of the invention is evaluated in a xenograft model of RS4;11 leukaemia cells.

1x10⁷ RS4;11 cells are grafted sub-cutaneously into immunosuppressed mice (SCID strain). 25 to 30 days after the graft, when the tumour mass has reached about 150 mm³, the mice are treated orally with the various compounds in two different regimes (daily treatment for five days per week for two weeks, or two treatments weekly for two weeks). The tumour mass is measured twice weekly from the start of treatment.


The compounds of the invention have anti-tumour activities, by the oral route, in the RS4;11 leukaemia model (acute lymphoblastic leukaemia) with $\Delta T/C$ (qualification parameter of the activity of a product, which is defined as the ratio tumour volume of the treated group/tumour volume of the untreated control group) ranging from -15 to -56% related to tumour regression. The results obtained therefore show that the compounds of the invention are capable of inducing significant tumour regression during the treatment period.

EXAMPLE F: Pharmaceutical composition: Tablets

	1000 tablets containing a dose of 5 mg of a compound selected from Examples 1 to 160	5 g
	Wheat starch	20 g
	Maize starch.....	20 g
5	Lactose.....	30 g
	Magnesium stearate	2 g
	Silica	1 g
	Hydroxypropylcellulose	2 g


CLAIMS

1- Compound of formula (I):



wherein:

- ◆ X and Y represent a carbon atom or a nitrogen atom, it being understood that they may not simultaneously represent two carbon atoms or two nitrogen atoms,

- ◆ the Het moiety of the group  represents an optionally substituted, aromatic or non-aromatic ring composed of 5, 6 or 7 ring members, which may contain, in addition to the nitrogen represented by X or by Y, from one to 3 hetero atoms selected independently from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom, a linear or branched (C₁-C₆)alkyl group or a group -C(O)-O-Alk wherein Alk is a linear or branched (C₁-C₆)alkyl group,

- ◆ R₁ and R₂ independently of one another represent a hydrogen atom or a linear or branched (C₁-C₆)alkyl group,

or R₁ and R₂ form with the nitrogen atom carrying them a heterocycloalkyl composed of from 4 to 7 ring members, which may contain, in addition to the nitrogen atom, another hetero atom selected from oxygen, sulphur, SO₂ and NR

wherein R represents a hydrogen atom, a linear or branched (C₁-C₆)alkyl group, a (C₁-C₆)alkylsulphonyl group, a linear or branched (C₁-C₆)polyhaloalkyl group or a group -C(O)-O-Alk wherein Alk is a linear or branched (C₁-C₆)alkyl group,

5 ♦ R₃ represents a linear or branched (C₁-C₆)alkyl group, a (C₂-C₆)alkenyl group, a (C₂-C₆)alkynyl group, a cycloalkyl group, a (C₄-C₁₀)cycloalkyl-(C₁-C₆)alkyl group wherein the alkyl group may be linear or branched, an aryl group or a heteroaryl group,

♦ R₄ represents an aryl, heteroaryl, cycloalkyl or linear or branched (C₁-C₆)alkyl group,

10 ♦ R₅ represents a hydrogen atom or a halogen atom,


♦ R_a, R_b, R_c and R_d independently of one another represent a hydrogen atom, a halogen atom, a linear or branched (C₁-C₆)alkyl group, a linear or branched (C₁-C₆)alkoxy group, a hydroxy group, a linear or branched (C₁-C₆)polyhaloalkyl group, or a trifluoromethoxy group, or the substituents of one of the pairs (R_a,R_b),
15 (R_b,R_c) or (R_c,R_d) form together with the carbon atoms carrying them a ring composed of from 5 to 7 ring members, which may contain from one to 3 hetero atoms selected from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom, a linear or branched (C₁-C₆)alkyl group or a group -C(O)-O-Alk wherein Alk is a
20 linear or branched (C₁-C₆)alkyl group, it also being understood that one or more carbon atoms of the ring defined hereinbefore may be deuterated,

it being understood that:

- "aryl" means a phenyl, naphthyl, biphenyl or indenyl group,
- "heteroaryl" means any mono- or bi-cyclic group composed of from 5 to 10 ring
25 members, having at least one aromatic moiety and containing from 1 to 3 hetero atoms selected from oxygen, sulphur and nitrogen,
- "cycloalkyl" means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 4 to 10 ring members,


it being possible for the alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so
30 defined to be substituted by from 1 to 3 groups selected from optionally substituted linear

or branched (C₁-C₆)alkyl, (C₃-C₆)spiro, linear or branched (C₁-C₆)alkoxy, (C₁-C₆)alkyl-S-, hydroxy, oxo (or *N*-oxide where appropriate), nitro, cyano, -COOR', NR'R'', linear or branched (C₁-C₆)polyhaloalkyl, trifluoromethoxy, (C₁-C₆)alkylsulphonyl or halogen, it being understood that R' and R'' independently of one another represent a hydrogen atom or a linear or branched (C₁-C₆)alkyl group,

it being possible for the Het moiety of the group  defined hereinbefore to be substituted by a group selected from linear or branched (C₁-C₆)alkyl, hydroxy, NR₁'R₁'' and halogen, it being understood that R₁' and R₁'' have the same definitions than the groups R' and R'' mentioned hereinbefore,

their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.

2- Compound of formula (I) according to claim 1, wherein the group



represents one of the following groups: 5,6,7,8-tetrahydroindolizine optionally substituted by a hydroxy, indolizine, 1,2,3,4-tetrahydropyrrolo[1,2-*a*]pyrazine, *tert*-butyl 3,4-dihydropyrrolo[1,2-*a*]pyrazine-2(1*H*)-carboxylate, 3,4-dihydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine, 2,3-dihydro-1*H*-pyrrolizine optionally substituted by a hydroxy, 6,7,8,9-tetrahydro-5*H*-pyrrolo[1,2-*a*]azepine or pyrrolo[1,2-*a*]pyrazine.

3- Compound of formula (I) according to claim 1, wherein R₁ and R₂ each represents an alkyl group optionally substituted by a methoxy, or R₁ and R₂ form with the nitrogen atom carrying them a heterocycloalkyl selected from the following groups: morpholine optionally substituted by one or more linear or branched (C₁-C₆)alkyl(s), oxidomorpholine, thiomorpholine 1,1-dioxide, 1,4-oxazepan, 3-methoxypyrrolidine, 3,3-difluoropyrrolidine, 3-methoxyazetidine, 3-fluoroazetidine, oxopiperazine or piperazine, the last two groups being substituted by a linear or branched (C₁-C₆)alkyl group, linear or branched (C₁-C₆)-polyhaloalkyl group or methylsulphonyl group.

4- Compound of formula (I) according to claim 1, wherein R_a and R_d each represents a

hydrogen atom, and (R_b,R_c) form together with the carbon atoms carrying them a 1,3-dioxolane group wherein one of the carbon atoms is optionally deuterated, a 1,4-dioxane group, a 1,4-dioxepane group, or R_a, R_c and R_d each represents a hydrogen atom and R_b represents a halogen, a methyl, a methoxy, an ethoxy, a trifluoromethyl or a trifluoromethoxy.

5- Compound of formula (I) according to claim 1, wherein R₄ represents a 4-hydroxyphenyl group, a 3-fluoro-4-hydroxyphenyl group or a 5-hydroxypyrimidine group.

6- Compound of formula (I) according to claim 1, wherein R₃ represents a group selected from phenyl, indole, indoline, 1,2,3,4-tetrahydroquinoline, 3,4-dihydro-2*H*-1,4-benzoxazine, indane, 1*H*-indazole, 1*H*-pyrrolo[2,3-*b*]pyridine, pyrimidine, cyclobutylmethyl, cyclopropylmethyl, 1*H*-pyrazole, pyridine, pyridazine, those groups optionally having one or more substituents selected from halogen, linear or branched (C₁-C₆)alkyl, cyano and linear or branched (C₁-C₆)alkoxy.

7- Compound of formula (I) according to claim 1, selected from the following group:

- *N*-(4-hydroxyphenyl)-3-{6-[(*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(*1H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl}-*N*-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- 3-{5-chloro-2-[(*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(*1H*)-isoquinolinyl)carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- *N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indazol-5-yl)-3-{2,2-dideuterio-6-[(*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(*1H*)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- *N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indazol-5-yl)-3-(6-{[(*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(*1H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide,
- *N*-(4-hydroxyphenyl)-3-{7-[(*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(*1H*)-isoquinolinyl)carbonyl]-2,3-dihydro-1,4-benzodioxin-6-yl}-*N*-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide,

- *N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-{6-[[((3*S*)-3-[(4-methyl-1-piperazinyl)methyl]-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-1-indolizine carboxamide,
- *N*-[4-(hydroxy)phenyl]-*N*-(1-methyl-1*H*-indol-5-yl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- *N*-(4-hydroxyphenyl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-*N*-phenyl-1-indolizine carboxamide,
- 3-{5-chloro-2-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-1-indolizine carboxamide,
- 6-{5-chloro-2-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(3-fluoro-4-methylphenyl)-*N*-(4-hydroxyphenyl)-3,4-dihydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine-8-carboxamide,
- 3-(5-chloro-2-[[((3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl]phenyl)-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-pyrazol-4-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide,
- *N*-(3-fluoro-4-methylphenyl)-*N*-(4-hydroxyphenyl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- *N*-[4-(hydroxy)phenyl]-*N*-(1-methyl-2,3-dihydro-1*H*-indol-5-yl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- 3-{5-chloro-2-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-2,3-dihydro-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- *N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-{6-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-1-indolizine carboxamide,
- 3-{5-chloro-2-[[((3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-2,3-dihydro-1*H*-indol-5-yl)-1-indolizine carboxamide,

- 6-{5-chloro-2-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-phenyl-3,4-dihydro-1*H*-pyrrolo[2,1-*c*]-[1,4]oxazine-8-carboxamide,
- *N*-(3-fluorophenyl)-*N*-(4-hydroxyphenyl)-3-(6-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide,

their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.


8- Compound of formula (I) according to claim 1, selected from the following group:

- *N*-(4-hydroxyphenyl)-3-{6-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-*N*-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- 3-{5-chloro-2-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- *N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indazol-5-yl)-3-{2,2-dideuterio-6-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- *N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indazol-5-yl)-3-(6-{[(3*S*)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1*H*)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide,
- *N*-(4-hydroxyphenyl)-3-{7-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-2,3-dihydro-1,4-benzodioxin-6-yl}-*N*-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- *N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-3-{6-[[[(3*S*)-3-[(4-methyl-1-piperazinyl)methyl]-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl]-1-indolizine carboxamide,
- *N*-[4-(hydroxy)phenyl]-*N*-(1-methyl-1*H*-indol-5-yl)-3-{6-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-5,6,7,8-tetrahydro-1-indolizine carboxamide,
- *N*-(4-hydroxyphenyl)-3-{6-[[[(3*S*)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1*H*)-

- isoquinoliny]carbonyl]-1,3-benzodioxol-5-yl}-*N*-phenyl-1-indolizine carboxamide,
- 3-{5-chloro-2-[(*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(*1H*)-isoquinoliny]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-indol-5-yl)-1-indolizine carboxamide,
 - 5 - 6-{5-chloro-2-[(*(3S)*-3-(4-morpholinylmethyl)-3,4-dihydro-2(*1H*)-isoquinoliny]carbonyl]phenyl}-*N*-(3-fluoro-4-methylphenyl)-*N*-(4-hydroxyphenyl)-3,4-dihydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine-8-carboxamide,
 - 3-(5-chloro-2-{[(*(3S)*-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(*1H*)-yl]carbonyl]phenyl}-*N*-(4-hydroxyphenyl)-*N*-(1-methyl-1*H*-pyrazol-4-yl)-5,6,7,8-
 - 10 tetrahydroindolizine-1-carboxamide,


their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.

9- Process for the preparation of a compound of formula (I) according to claim 1, characterised in that there is used as starting material the compound of formula (II):




15 wherein R_a , R_b , R_c and R_d are as defined for formula (I),

which compound of formula (II) is subjected to a Heck reaction, in an aqueous or organic medium, in the presence of a palladium catalyst, of a base, of a phosphine and of the compound of formula (III):




wherein the groups X, Y and Het are as defined for formula (I),

to obtain the compound of formula (IV):




wherein R_a , R_b , R_c , R_d , X, Y and Het are as defined for formula (I),

the aldehyde function of which compound of formula (IV) is oxidised to the carboxylic acid to form the compound of formula (V):




wherein R_a , R_b , R_c , R_d , X, Y and Het are as defined for formula (I),

which compound of formula (V) is then subjected to peptide coupling with a compound of formula (VI):



wherein R_1 , R_2 and R_5 are as defined for formula (I),

to yield the compound of formula (VII):



wherein R_a , R_b , R_c , R_d , R_1 , R_2 , R_5 , X, Y and Het are as defined for formula (I),

the ester function of which compound of formula (VII) is hydrolysed to yield the
 5 carboxylic acid or the corresponding carboxylate, which may be converted into an acid
 derivative such as acyl chloride or the corresponding anhydride before being coupled with
 an amine NHR_3R_4 wherein R_3 and R_4 have the same meanings as for formula (I), to yield
 the compound of formula (I),

which compound of formula (I) may be purified according to a conventional separation
 10 technique, which is converted, if desired, into its addition salts with a pharmaceutically
 acceptable acid or base and which is optionally separated into its isomers according to a
 conventional separation technique,

it being understood that at any moment considered appropriate during the course of the
 process described above, some groups (hydroxy, amino...) of the starting reagents or of
 15 the synthesis intermediates can be protected and subsequently deprotected, as required by

the synthesis,

10- Process according to claim 9 for the preparation of a compound of formula (I) wherein one of the groups R_3 and R_4 is substituted by a hydroxy function, characterised in that the amine NHR_3R_4 is subjected beforehand to a protection reaction of the hydroxy function prior to coupling with the carboxylic acid formed from the compound of formula (VII), or with a corresponding acid derivative thereof, the resulting protected compound of formula (I) subsequently undergoes a deprotection reaction and is then optionally converted into one of its addition salts with a pharmaceutically acceptable acid or base.

11- Pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 8 or an addition salt thereof with a pharmaceutically acceptable acid or base in combination with one or more pharmaceutically acceptable excipients.

12- Pharmaceutical composition according to claim 11 for use as pro-apoptotic agents.

13- Pharmaceutical composition according to claim 11 for use in the treatment of cancers and of immune and auto-immune diseases.

14- Pharmaceutical composition according to claim 11 for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, follicular lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer and small-cell lung cancer.

15- Use of a pharmaceutical composition according to claim 11 in the manufacture of medicaments for use as pro-apoptotic agents.

16- Use of a pharmaceutical composition according to claim 11 in the manufacture of medicaments for use in the treatment of cancers and of immune and auto-immune diseases.

17- Use of a pharmaceutical composition according to claim 11 in the manufacture of medicaments for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, follicular lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer and small-cell lung cancer.

18- Compound of formula (I) according to any one of claims 1 to 8, or an addition salt thereof with a pharmaceutically acceptable acid or base, for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, follicular lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer and small-cell lung cancer.

19- Use of a compound of formula (I) according to any one of claims 1 to 8, or an addition salt thereof with a pharmaceutically acceptable acid or base, in the manufacture of medicaments for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, follicular lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer and small-cell lung cancer.

20- Association of a compound of formula (I) according to any one of claims 1 to 8 with an anti-cancer agent selected from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors, kinase inhibitors and antibodies.

21- Pharmaceutical composition comprising an association according to claim 20 in combination with one or more pharmaceutically acceptable excipients.

22- Association according to claim 20 for use in the treatment of cancers.

23- Use of an association according to claim 20 in the manufacture of medicaments for use in the treatment of cancers.

24- Compound of formula (I) according to any one of claims 1 to 8 for use in association with radiotherapy in the treatment of cancers.